Btbd11 is an inhibitory interneuron specific synaptic scaffolding protein that supports excitatory synapse structure and function

AUTHORS:

Alexei M Bygrave[1], Ayesha Sengupta[2], Ella P Jackert[1], Mehroz Ahmed[1], Beloved Adenuga[1], Erik Nelson[1], Hana L Goldschmidt[1], Richard C Johnson[1], Haining Zhong[3], Felix L Yeh[4], Morgan Sheng[5], Richard L Huganir[1,6]*.

AFFILIATIONS:

[1] Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

[2] National Institute on Drug Abuse, Bayview Boulevard, Baltimore, MD 21224, USA.

[3] Vollum Institute, Oregon Health & Science University, Portland, OR 97239, USA.

[4] Department of Neuroscience, Genentech Inc., South San Francisco, CA, 94080, USA.

[5] Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.

[6] Kavli Neuroscience Discovery Institute, Johns Hopkins University, Baltimore, MD 21205, USA.

*Correspondence to: rhuganir@jhmi.edu

SUMMARY (150 words)

Synapses in the brain exhibit cell-type-specific differences in basal synaptic transmission and plasticity. Here, we evaluated cell-type-specific differences in the composition of glutamatergic synapses, identifying Btbd11, as an inhibitory interneuron-specific synapse-enriched protein. Btbd11 is highly conserved across species and binds to core postsynaptic proteins including Psd-95. Intriguingly, we show that Btbd11 can undergo liquid-liquid phase separation when expressed with Psd-95, supporting the idea that the glutamatergic post synaptic density in synapses in inhibitory and excitatory neurons exist in a phase separated state. Knockout of Btbd11 from inhibitory interneurons decreased glutamatergic signaling onto parvalbumin-positive interneurons. Further, both *in vitro* and *in vivo*, we find that Btbd11 knockout disrupts network activity. At the behavioral level, Btbd11 knockout from interneurons sensitizes mice to pharmacologically induced hyperactivity following NMDA receptor antagonist challenge. Our findings identify a cell-type-specific protein that supports glutamatergic synapse function in inhibitory interneurons—with implication for circuit function and animal behavior.

KEYWORDS

Btbd11, inhibitory interneurons, glutamatergic synapse, parvalbumin, liquid-liquid phase separation

INTRODUCTION

The postsynaptic density (PSD) of glutamatergic synapses in the brain is a densely packed protein rich structure that supports excitatory synaptic transmission and synaptic plasticity. Presently, our understanding of the PSD largely comes from studying excitatory neurons (ENs) which make up 80-90% of neurons in cortical and hippocampal circuits (Hu et al., 2014). Impaired function of inhibitory interneurons (INs) is associated with psychiatric disease and neurological disorders (Lewis et al., 2005; Lisman et al., 2008; Marín, 2012). More specifically, impaired glutamatergic excitation of INs, particularly parvalbumin (PV) positive INs, is linked to the pathophysiology of schizophrenia (Lewis et al., 2005; Lisman et al., 2008). PV-INs have been extensively studied, and their role in regulating circuit activity (*i.e.*, controlling the precise timing of EN cell firing), supporting rhythmic neuronal activity (*i.e.*, generation of gamma oscillations), and controlling animal behavior is well documented (Cardin et al., 2009; Donato et al., 2013; Kuhlman et al., 2013; Mann et al., 2005; Sohal et al., 2009). Interestingly, both basal glutamatergic transmission and plasticity in INs (including PV-INs) is different to in ENs (Chang et al., 2010; Geiger et al., 1995; Lamsa et al., 2007; Matta et al., 2013). However, very little is known about the molecular composition of the IN glutamatergic post-synaptic density (inPSD) and whether cell-type-specific specializations exist to govern these distinct properties.

Recent evidence indicates that many components of the glutamatergic PSD undergo liquid-liquid phase separation (LLPS), suggesting the PSD likely exists as a phase-separated structure that aids synapse function (Chen et al., 2020; Feng et al., 2019; Zeng et al., 2016, 2019). LLPS could be particularly important for the stability and function of inPSD's, which are frequently located directly on the dendritic shaft of INs (Hu et al., 2014) rather than being nested within dendritic spines as is common in ENs (but note Keck et al., 2011 and Sancho et al., 2018). Molecular mechanisms must support PSD stability, as shaft glutamatergic synapses located within PV-INs are on average more stable than their counterparts in INs when assessed with longitudinal imaging *in vivo* (Melander et al., 2021). Here, we use a combination of genetic tools and proteomics to identify cell-type-specific PSD proteins. We characterize Btbd11 as a novel inPSD which undergoes LLPS and regulates glutamatergic synapses in INs as well as neuronal circuit function.

RESULTS

Identification of Btbd11 as a novel inPSD protein

To gain insights into the molecular composition of inPSDs, we bred conditional Psd-95-GFP knockin mice (second generation mice based on Fortin et al., 2014) with vGAT^Cre or CaMKII^Cre animals, tagging a core scaffold protein at glutamatergic synapses in INs or ENs, respectively. We collected cortex and hippocampal tissue from these animals and performed GFP-immunoisolation experiments (**Figure**

69 **1A**). To compensate for the lower abundance of INs we pooled samples from 4 vGAT[Cre]:Psd-95-GFP

70 mice to compare with 1 CaMKII[Cre]:Psd-95-GFP mouse. Utilizing mass spectrometry and label free

71 quantification, we identified immuno-isolated PSD complexes preferentially originating from INs or ENs.

72 Normalising to the amount of Psd-95 we found proteins that were specifically enriched in INs (**Figure 1B**,

73 **Table S1**). Such proteins were considered putative inPSD proteins. The top hit was Btbd11, an ankyrin

74 repeat and BTB/POZ domain-containing protein.

75 Btbd11 was previously identified in both Psd-95 pull-down and proximity labelling experiments

76 (Fernández et al., 2009; Uezu et al., 2016), but its cell-type-specific expression pattern was not explored.

77 Furthermore, a biological function of Btbd11 remains completely unknown, in the brain or otherwise. We

78 generated and validated an antibody against Btbd11 (**Figure S1**) as no commercial antibodies were

79 available. To confirm our mass spectrometry results, we repeated GFP-immuno-isolation experiments

80 and used western blots to confirm that Btbd11 was selectively pulled-down from IN samples (**Figure 1C**).

81 We then explored published RNA datasets and found that Btbd11 mRNA expression is exclusive to INs

82 in the cortex and hippocampus of mice (Furlanis et al., 2019; Tasic et al., 2016) (**Figure 1D**).

83 Using immunofluorescence and our antibody for Btbd11 in cultured rat hippocampal neurons we

84 observed punctate Btbd11 expression which co-localized with Psd-95 in Gad67-positive INs (**Figure 1E**).

85 As a secondary validation, and to circumvent any possible issues with non-specific antibody binding, we

86 designed CRISPR knockin constructs to label endogenous Btbd11 using the ORANGE method (Willems

87 et al., 2020). We opted to tag Btbd11 at the N-terminus with GFP, and electroporated rat primary cultures

88 cortical neurons with the knockin construct alongside a mCherry cell-fill (**Figure 1F**). We observed a

89 sparse population of cells with punctate GFP signal which, as expected, also were positive for Gad67

90 (**Figure 1G**). Indeed, of the 31 KI cells imaged 100% were also Gad67-positive (**Figure 1H**), confirming

91 the IN-specific expression of Btbd11 in cortical neurons. We next coupled this CRISPR knockin approach

92 with immunofluorescence to evaluate if Btbd11 puncta were enriched at synapses. GFP-Btbd11 puncta

93 overlapped with Psd-95 puncta, indicating the protein is found at glutamatergic synapses (**Figure 1I**). In

94 contrast, there was very little overlap with Gephyrin, a marker of GABAergic inhibitory synapses (**Figure

95 1J**). We quantified the relative enrichment at glutamatergic synapses by calculating the distances

96 between GFP-Btbd11 puncta and Psd-95 or Gephyrin puncta and found that the puncta-to-puncta

97 distance was considerably smaller at glutamatergic synapses (**Figure 1K**).

98 Collectively, these data highlight that there are cell-type-specific differences in the composition of

99 glutamatergic synapses and establish Btbd11 as a novel inPSD protein that is selectively located at

100 glutamatergic synapses.

Figure 1. Identification of Btbd11 as a novel inPSD protein.

(A) Schematic of Psd-95-GFP knockin in CaMKII or vGAT positive neurons to label excitatory and inhibitory neurons, respectively, for use in immunoisolation experiments. (B) Proteins identified using semi-quantitative mass spectrometry following PSD-95-GFP immunoisolation expressed as a vGAT/CaMKII ratio. Before calculating the ratio, proteins were normalized to levels of Psd-95. (C) Psd-95-GFP immunoisolation with CaMKII:Psd-95-GFP or 5x vGAT:Psd-95-GFP (pooled) mice followed by western blots for GFP (detecting Psd-95-GFP, the "bait") from 10% of the pull-down, or Btbd11 (a candidate inPSD) from 40% of the pull-down. (D) Assessment of different RNA databases showing that Btbd11 RNA is highly enriched in INs in the cortex and hippocampus. (E) Immunofluorescence in rat primary hippocampal neurons (DIV16) for Gad-67, Btbd11 and Psd-95. The region in

4

110 the yellow dashed box is enlarged below. (F) Schematic of the CRISPR knockin strategy used to label endogenous
111 Btbd11. GFP was targeted to the N-terminal region of Btbd11. (G) Example of GFP-Btbd11 knockin cell from primary
112 cultured rat cortical neurons electroporated with knockin constructs and a mCherry cell-fill. Immunofluorescence
113 was used to boost the GFP signal (green) and to identify Gad-67 positive cells (a marker of INs). Yellow arrows
114 indicate Gad-67 positive cells (with observed cytoplasmic signal) and orange arrows indicate Gad-67 negative cells
115 (the was some non-specific nuclear signal). (H) All of the 31 GFP-Btbd11 knockin cells were also Gad-67 positive,
116 showing the specificity of Btbd11 in INs. (I and J) Zoom in along the dendrites of GFP-Btbd11 knockin cells with
117 immunofluorescence for Psd-95 or Gephyrin, respectively. Yellow arrows indicate a subset of Btbd11 puncta. (K)
118 Cumulative frequency plots indicating the puncta-to-puncta distance of Btbd11 with Psd-95 (magenta) or Gephyrin
119 (blue).
120

121 **Btbd11 contains a PDZ binding motif which interacts with PDZ1,2 of Psd-95**

122   Btbd11 is annotated to contain 5 ankyrin repeats, a BTB domain, and region of predicted disorder

123 (www.uniprot.org). In addition, the C-terminal amino acids are consistent with a PDZ binding motif (PBM;

124 **Figure 2A**). Utilizing a protein structure prediction algorithms from AlphaFold (Senior et al., 2020) we

125 observed that Btbd11 contains additional regions of potential disorder (**Figure 2B, Video S1**).

126 Interestingly, the C-terminal region of Btbd11 is highly conserved between species, highlighting the

127 potential importance of the PBM (**Figure 2C**). PBM's support interactions with PDZ domain containing

128 proteins, including the membrane-associated guanylate kinases (MAGUK) family of proteins such as

129 Psd-95 used as "bait" in our immune-isolation experiment. We hypothesized that the PBM of Btbd11

130 might support a direct interaction with the PDZ domains of Psd-95.

131   To test if there is a direct interaction between Btbd11 and Psd-95 through PBM-PDZ domain

132 interactions we used a yeast 2-hybrid approach. We created a fusion protein consisting of a DNA binding

133 domain and the C-terminus of Btbd11 +/- the PBM as "bait", and used an activation domain-Psd-95 fusion

134 protein containing different combinations of the 3 PDZ domains as "prey" (**Figure 2D**). We only observed

135 yeast growth, a readout of a protein-protein interaction, when PDZ domains 1,2 or 1,2,3 were present

136 (**Figure 2E**). Btbd11 lacking the PBM did not interact with PDZ 1,2,3 of Psd-95, highlighting the necessity

137 of the PBM for binding.

138   To complement the yeast 2-hybrid approach we adopted a GST pull-down strategy in mammalian

139 cells. We cloned full-length GST-Btbd11 +/- the PBM and expressed these GST fusion proteins (or GST

140 only) in HEK cells alongside Psd-95-mCherry, then lysed the cells and performed a GST pull-down. We

141 found that Btbd11 was able to pull-down Psd-95-mCherry, but only when the PBM was present (**Figure

142 2F,G**). To confirm the binding was mediated by PDZ1,2 of Psd-95, we cloned mutants of Psd-95-mCherry

143 in which the individual PDZ domain function was disrupted (dPDZ1-3) based on previously generated

144 mutants (Imamura et al., 2002). Confirming our observations in yeast, we found diminished binding to

145 Btbd11 with Psd-95 harbored mutations in PDZ1,2 or PDZ1,2,3. Mutations to PDZ3 alone had no

146 discernable effect on Btbd11 binding, highlighting the specificity of the interaction.

147

5

A Uniprot annotations — Disordered, Ank 1, Ank 2, Ank 3, Ank 4, Ank 5, BTB, PBM, GSVV

B Alpha fold prediction — Ank repeats, PBM, Disordered, BTB

C

	Hydophobic Positive Negative	residue #
Human	DVLQDLQRTLAI RIQSIHLSSSKGSVV	1104
Chimpanzee	DVLQDLQRTLAI RIQSIHLSSSKGSVV	1101
Cow	DVLQDLQRTLAI RIQSIHLSSSKGSVV	1108
Rat	DVLQDLQRTLAI RIQSIHLSSSKGSVV	1109
Mouse	DVLQDLQRTLAI RIQSIHLSSSKGSVV	1109
Zebrafish	DVLHDLE KTLATRIRSIHLSSSKGS IV	1012

D "Prey" Activation domain — DNA binding domain, BTBD11 "Bait", GAL4 UAS, HIS3 reporter gene, X. Prey and Bait interaction, Survival on HIS negative plates, GAL4 UAS, HIS3 reporter gene

E

Bait protein	Prey protein	Clone: 1 2 3	Growth (Y/N)
Btbd11 C-term	Psd-95 PDZ-1		N
Btbd11 C-term	Psd-95 PDZ-2		N
Btbd11 C-term	Psd-95 PDZ-3		N
Btbd11 C-term	Psd-95 PDZ-1,2		Y
Btbd11 C-term	Psd-95 PDZ-2,3		N
Btbd11 C-term	Psd-95 PDZ-1,2,3		Y
Btbd11 C-term	Empty		N
Btbd11 ΔPBM	Psd-95 PDZ-1,2,3		N

F Input / Pull-down — GST-Btbd11, GST-Btbd11ΔPBM, GST; Psd-95-mCherry: + + + / + + +; WB: dsRED (Psd-95-mCherry); WB: GST

H Input / Pull-down — WT, dPDZ1,2, dPDZ3, dPDZ1,2,3, WT; GST-Btbd11: + + + + - / + + + + -; GST: - - - - + / - - - - +; WB: dsRED (Psd-95-mCherry); WB: GST

G Psd-95 pull down (% of control); GST-Btbd11, GST-Btbd11ΔPBM, GST; ***

I Psd-95 pull down (% of control); WT, dPDZ1,2, dPDZ3, dPDZ1,2,3, WT (No Btbd11); ***, n.s., ***

148

149 **Figure 2.** Btbd11 contains a PDZ binding motif which interacts with PDZ1,2 of Psd-95.
150 (A) Schematic depiction of Btbd11 with annotations from Uniprot. Red = disordered, gray = ankyrin repeats (Ank),
151 blue = BTB domain (BTB), magenta = PDZ binding motif (PDM). (B) Predicted structure of Btbd11 from AlphaFold
152 with domains shaded as in (A). (C) C-terminal region of Btbd11 in different species showing the conservation of the
153 PBM. (D) Schematic of targeted yeast two-hybrid experiment to assess binding of Btbd11 with different PDZ
154 domains of Psd-95. (E) Results from targeted yeast two-hybrid experiment with growth indicating an interaction
155 between Btbd11 and Psd-95. (F) GST pull-down experiments evaluating the ability of GST-Btbd11 or a mutant
156 lacking the PBM (GST-Btbd11ΔPBM) to interact with Psd-95-mCherry in HEK cells. GST only was included as a
157 negative control. (G) Qualification of Psd-95-mCherry pulled-down by GST-Btbd11 or GST-Btbd11ΔPBM. (H) GST
158 pull-down experiments in HEK cells evaluating the ability of GST-Btbd11 to interact with Psd-95-mCherry point
159 mutants designed to disrupt PDZ domain binding. (I) Quantification of Psd-95-mCherry mutants pulled-down by
160 GST-Btbd11. Error bars display S.E.M. *** indicates p < 0.001. *See* **Table S2** for full statistical used for this and all
161 subsequent analyses.
162

163   Having established a direct interaction with Psd-95, we sought to identify other potential

164 interaction partners. We conducted a yeast 2-hybrid screen using either the BTB domain or the C-terminal

165 region containing the PBM of Btbd11 as "bait". From the screen with the C-terminus of Btbd11 we

166 identified well known PDZ-containing synaptic proteins including Psd-93, Sap-102 and Pick1 as putative

167 interactors (**Figure S2**). Using the BTB domain we pulled out Ataxin1 and Ataxin-1like as potential

168 interactors (**Figure S2**). Although not yet tested we expect that the tandem ankyrin repeats of Btbd11

169 facilitate other protein-protein interactions, as is common for proteins with ankyrin repeats (Mosavi et al.,

170 2004).

171   Taken together, these data show that Btbd11 contains a highly conserved C-terminal PBM which

172 mediates a direct interaction with PDZ1,2 of Psd-95. Furthermore, our yeast 2-hybrid screen indicates

173 that Btbd11 can interact with other key synaptic proteins, including other MAGUK family members and

174 proteins known to regulate the trafficking of glutamate receptors (*i.e.*, Pick1).

175

176 **Liquid-liquid phase separation of Btbd11 when expressed with Psd-95**

177   We next sought to explore the properties of exogenously expressed Btbd11. To do this we cloned

178 GFP and mCherry tagged Btbd11 with or without the PBM necessary for an interaction with Psd-95. In

179 HEK cells expression of GFP-Btbd11 led to the formation of striking fibril-like structures (**Figure 3A**).

180 Remarkably, when Psd-95-mCherry was expressed alongside GFP-Btbd11 the fibril structures were

181 replaced with large spherical intracellular droplets with a high degree of Btbd11 and Psd-95 colocalization

182 (**Figure 3B,C**). Droplet formation was critically dependent upon an interaction between Btbd11 and Psd-

183 95, since deletion of the PBM of Btbd11 abolished their formation (**Figure 3D,E**). By contrast, formation

184 of fibrils was not dependent upon the PBM (see **Figure S3** for quantification of fibril and droplet formation

185 under different conditions).

186   The spherical puncta formed by Btbd11 and Psd-95 were reminiscent of biomolecular

187 condensates arising from liquid-liquid phase separation (LLPS) of abundant PSD proteins including

7

188 SynGAP and Psd-95 (Zeng et al., 2016). A hallmark of LLPS is fluorescent recovery after photobleaching

189 (FRAP), indicating a dynamic exchange of biomolecules between putative condensates and the

190 surrounding cytosol—a phenomena that is not expected if puncta are formed from protein aggregates

191 locked into a solid state. To test this, we transiently expressed mCherry-Btbd11 with Psd-95-GFP (**Figure**

192 **3F**) or Psd-95-mCherry with GFP-Btbd11 (**Figure 3G**) and photobleached individual puncta in HEK cells.

193 We observed signal recovery for both Btbd11 (**Figure 3H**) and Psd-95 (**Figure 3I**), with Psd-95 recovering

194 at a faster rate (**Figure 3J**).

195 LLPS can be facilitated by proteins which contain regions of intrinsic disorder (Uversky, 2017).

196 Btbd11 contains predicted regions of disorder within its N-terminal region (**Figure 2A,B**) which we

197 speculated could promote LLPS. To test this, we cloned a GFP- and mCherry-Btbd11 that lacked a large

198 portion of the N-terminus upstream of the ankyrin repeats (5xANK-BTB). When expressed with Psd-95,

199 large aggregates formed in which there was also a high degree of co-localization between 5xANK-BTB

200 and Psd-95 (**Figure S3**). However, in addition to lacking the spherical droplets observed with full-length

201 Btbd11, the 5xANK-BTB assemblies did not show FRAP, indicating the structures were unlikely to be

202 liquid-like assemblies (**Figure S3**).

203 A further hallmark of LLPS is the coalescence of puncta over time to form larger droplets. Through

204 time-lapse imaging of HEK cells expressing GFP-Btbd11 and Psd-95-mCherry we observed fusion of

205 puncta over time (**Figure 3K**, **Video S2**). Frequently purified proteins—or portions of proteins—are mixed

206 *in vitro* to validate LLPS. Our attempts to purify Btbd11 to conduct such experiments have so far been

207 unsuccessful, likely because Btbd11 readily forms fibrils which make protein purification challenging.

208 Therefore, to get an orthogonal validation that the puncta were true "membrane-less organelles" we

209 performed electron microscopy on HEK cells expressing either GFP-Btbd11 alone, or in combination with

210 Psd-95-mCherry. As expected, considering on our fluorescent imaging, in the Btbd11-only condition we

211 found cells with fibril-like structures (**Figure 3L**). We also observed fibril-like structures when Btbd11 was

212 expressed with Psd-95, but also identified droplet-like assemblies in the cytoplasm, which occasionally

213 also appeared to be impaled by the fibrils (**Figure 3M**). Critically, these droplets appeared electron dense

214 but clearly lacked any kind of lipid bilayer. Furthermore, we found examples of droplets that looked like

215 they could be in the process of fusion (**Figure 3O**).

216 While these data came from exogenously expressed Btbd11 in HEK cells we did observe putative

217 droplets in a CRISPR knockin cell in which endogenous Btbd11 was tagged with GFP in primary cortical

218 neurons (**Figure 3P**). Thus, under certain conditions, endogenous Btbd11 might form biomolecular

219 condensates at the cell body, in addition to being enriched at the synapse (**Figure 1G**).

8

Figure 3. Liquid-liquid phase separation of Btbd11 when expressed with Psd-95.

(A) Expression of GFP-Btbd11 (green) and an azurite cell-fill (blue) in HEK cells led to the formation of large fibril-like assemblies. Scale bar = 10μm. (B) Co-expression of GFP-Btbd11 (green) with Psd-95-mCherry (magenta) and

224 an azurite cell-fill (blue) led to the formation of spherical droplets in HEK cells. The region within the white box is
225 enlarged on the right (Zoom), and the yellow dotted line indicates where a line scan (C) is shown for Psd-95-
226 mCherry and GFP-Btbd11. (D) Co-expression of GFP-Btbd11ΔPBM (green) with Psd-95-mCherry (magenta) and
227 an azurite cell-fill (blue) in HEK cells led to the formation of fibril-like assemblies with the absence of spherical
228 droplets. The region within the white box is enlarged on the right (Zoom), and the yellow dotted line indicates where
229 a line scan (E) is shown for Psd-95-mCherry and GFP-Btbd11ΔPBM. (F and G) Fluorescence recovery after
230 photobleaching (FRAP) of mCherry-Btbd11 and Psd-95-mCherry co-expressed with Psd-95-GFP and GFP-Btbd11,
231 respectively. Note the difference in timescales for Btbd11 and Psd-95. Scale bar = 1μm. (H and I) Quantification of
232 fluorescence recovery for Btbd11 (n = 13) and Psd-95 (n = 15), respectively. Error bars indicate S.E.M. (J) Plot of
233 the exponential fit of FRAP data for Btbd11 (green) and Psd-95 (blue). (K) Longitudinal confocal imaging of a HEK
234 cell transfected with GFP-Btbd11 (green), Psd-95-mCherry (magenta) and an azurite cell-fill (blue). Yellow dotted
235 arrows indicate two puncta that come together and form a single droplet (solid yellow arrow). Scale bar = 1μm. (L
236 and M) Electron microscope images of HEK cells transfected with GFP-Btbd11 or GFP-Btbd11 and Psd-95-
237 mCherry, respectively. The black dotted box is enlarged on the right of each panel. Respective scale bars are
238 indicted at the bottom left of each image. In (M) the red arrow indicates a putative droplet observed with Btbd11
239 and Psd-95 co-expression but not with Btbd11 expression alone. (O) An example of a putative Btbd11 and Psd-95
240 droplet that looks to be in the process of fusion or fission with cyan arrows indicating the neck. (P) Example of a
241 GFP-Btbd11 rat primary cortical neuron with droplet-like assemblies in the cell body as well as puncta along the
242 dendrites (not-shown). White boxes are enlarged on the right-hand size. Respective scale bars are indicted at the
243 bottom left of each image.

245   These data strongly indicate that Btbd11 can undergo LLPS with Psd-95 in living cells, identifying

246 for the first time an inPSD-specific protein which promotes phase separation. Since LLPS at the PSD is

247 suggested to play important roles in synapse function, the ability of Btbd11 to promote LLPS of Psd-95

248 (expressed alone Psd-95 does not form intracellular droplets) could have important consequences on

249 synapse function.

Exogenous expression of Btbd11 stabilizes Psd-95 at glutamatergic synapses

252   Having observed the striking properties of exogenously expressed Btbd11 in HEK cells, we

253 wondered about the consequence of Btbd11 overexpression in neurons. To assess this, we expressed

254 GFP-Btbd11 in rat hippocampal neurons. Large fibril-like structures formed in the cell body and dendrites

255 of transfected cells (**Figure 4A**). These fibril structures were stable, as observed by a lack of FRAP when

256 a portion of the fibril was bleached (**Video S3**). GFP-Btbd11 was also observed at glutamatergic

257 synapses when imaged with higher magnification, as indicated by co-localization with Psd-95, but not

258 gephyrin (**Figure 4B**), confirming our previous observations with endogenously tagged Btbd11 (**Figure**

259 **1I-K**). We speculated that Btbd11's PBM would be necessary for proper synaptic targeting and confirmed

260 this by showing there was no synapse localization of Btbd11 that lacked a PBM (**Figure 4C,D**).

261   The formation of fibril-like structures is common to proteins which also undergo LLPS, with liquid

262 to solid phase transitions occurring at saturating concentrations (Alberti and Dormann, 2019; Molliex et

263 al., 2015). We tested if fibril formation was dose-dependent by expressing increasing amounts of GFP-

264 Btbd11 DNA (0.25 – 2μg/well) alongside a mCherry cell fill (**Figure 4E**). While there was variability in the

265 amount of DNA transfected within each transfection dose, clear patterns emerged whereby at high doses

10

266 almost all mCherry positive cells contained Btbd11 fibrils (**Figure 4F**). Interestingly, at the lower doses
267 we observed many cells that contained small droplet-like assemblies reminiscent of the LLPS
268 condensates observed in HEK cells (**Figure 4G**; and see **Figure 3**). We speculate that these droplets
269 form when Btbd11 interacts with endogenous Psd-95, and that the fibrils form when a concentration
270 threshold is surpassed. As fibril structures were not observed with our endogenous CRISPR labeling of
271 Btbd11 (at least under the basal conditions evaluated) we imagine that fibril formation is unlikely to be
272 physiologically relevant to cellular function—but highlights intriguing properties of the protein.

273   The stability of Psd-95 is the same in INs as in ENs, despite INs generally lacking dendritic spines
274 (Fortin et al., 2014). Indeed, we confirmed these observations with FRAP of overexpressed Psd-95-
275 mCherry in putative INs or ENs (**Figure S4**). It has been postulated that biomolecular condensation
276 through LLPS at the synapse might promote the stability of densely packed PSD proteins against the
277 forces of Brownian motion (Chen et al., 2020; Feng et al., 2019). We suspect that inPSDs have protein
278 specializations to promote their stability and function. Could Btbd11 promote the stability of Psd-95 at the
279 synapse, possibly by driving LLPS? To explore this possibility, we expressed Psd-95-mCherry with or
280 without GFP-Btbd11 in putative INs in hippocampal cultures identified with an Azurite cell-fill under control
281 of the mDlx enhancer (Dimidschstein et al., 2016). Psd-95 stability was monitored by FRAP of Psd-95-
282 mCherry puncta and the recovery curves compared with or without addition of GFP-Btbd11 (**Figure 4H**).
283 Psd-95-mCherry FRAP was slower in the presence of overexpressed Btbd11, indicating a larger
284 immobile fraction—or a stabilizing effect on Psd-95 at the synapse (**Figure 4I,J**). Intriguingly, when
285 Btbd11 was overexpressed in ENs (which normally totally lack Btbd11), no stabilization of Btbd11 was
286 observed (**Figure S4**). These data could be explained by the fact that ENs express high levels of known
287 Psd-95 interaction proteins (such as SynGAP) rendering additional Btbd11-dependent stabilization
288 redundant. Together, these data show that exogenously expressed Btbd11 forms intracellular droplets
289 and fibrils in a dose-dependent manner, and that Btbd11 can stabilize Psd-95 at the synapse in a cell-
290 type specific manner. It is possible that the stabilizing effect on Psd-95 results from Btbd11 promoting
291 LLPS at the PSD.

Figure 4. Exogenous expression of Btbd11 stabilizes Psd-95 at glutamatergic synapses.
(A) Confocal image from a primary cultured rat hippocampal neuron transfected with GFP-Btbd11 (green) and azurite as a cell-fill (blue) with prominent formation of fibril-like assemblies. Scale bar = 10μm. (B) Confocal image from a primary cultured putative IN transfected with GFP-Btbd11 (green), Psd-95-mCherry (magenta), mDlx-Azurite (blue) with immunohistochemistry for Gephyrin (yellow). The region within the white dotted box is enlarged on the right with different combinations of channels. Scale bars in the bottom left of the images. Note the lack of co-localization between GFP-Btbd11 and Gephyrin. (C) Schematic of GFP-Btbd11 and GFP-Btbd11ΔPBM constructs. (D) Confocal image of putative primary cultured hippocampal interneurons, identified with an azurite cell-fill (blue) under the control of the mDlx enhancer to drive expression in INs. Full-length GFP-Btbd11 (FL, left) and GFP-Btbd11ΔPBM (ΔPBM, right) shown in green was co-expressed with Psd-95-mCherry (magenta). Synaptic puncta were observed with the FL but not ΔPBM Btbd11 construct. Scale bar = 5μm. (E) Confocal image from transfected primary cultured rat hippocampal neurons with varying amounts of GFP-Btbd11 (green) and mCherry as a cell-fill (magenta). Scale bar = 10μm. (F and G) Quantification of the proportion of cells with fibrils (red bars) or droplets

12

305 (magenta bars), respectively, when GFP-Btbd11 is transfected in different quantities. (H) Live-cell confocal imaging
306 and FRAP experiments in putative INs (identified with mDlx-azurite) in which Psd-95-mCherry (magenta) is
307 bleached when expressed alone, or in the presence of Gfp-Btbd11 (green). The lower panels show FRAP of the
308 individual puncta labeled in the upper panels with a white arrow. Respective scale bars are indicted at the bottom
309 left of each image. (I) Quantification of Psd-95-mCherry FRAP under control conditions (black) or with
310 overexpression of Btbd11 (magenta). Error bars display S.E.M. (J) Quantification of the estimated recovery
311 maximum from an exponential fit of the FRAP data for each bleached punctum. Control data shown in black and
312 Btbd11 overexpression data in magenta. Error bars display S.E.M. * indicates p < 0.05.

313

314 **Btbd11 KO reduces glutamatergic signaling in PV-INs**

315 We next explored the effects of Btbd11 loss-of-function though genetic knockout by generating

316 Btbd11 gene trap mice using IVF and frozen sperm from the European Mutant Mouse Archive

317 (www.infrafrontier.eu). The gene trap mice did not show reduced levels of Btbd11 mRNA or protein

318 (**Figure S5**), probably due to a truncation previously reported in the gene-trap cassette of this line (Ryder

319 et al., 2013). By crossing the gene-trap mice with a constitutive Flp recombinase line we converted the

320 gene-trap mice into conditional knockout animals (Btbd11$^{F/F}$). We validated Btbd11 knockout using

321 primary cultured cortical neurons from Btbd11$^{F/F}$ mice with AAVs delivering GFP or GFP-Cre. There was

322 reliable loss of Btbd11 mRNA and protein in the presence of GFP-Cre, observed with Northern blots and

323 western blots, respectively (**Figure 5A,B**).

324 To create IN-specific Btbd11 knockout mice we bred vGAT$^{Cre/Wt}$ mice with Btbd11$^{F/F}$ animals to

325 generate litters of vGAT$^{Wt/Wt}$:: Btbd11$^{F/F}$ (CON) and vGAT$^{Cre/Wt}$::Btbd11$^{F/F}$ (vGAT-Btbd11 KO) animals.

326 Confirming our previous data that Btbd11 was specific to INs, we observed a total loss of Btbd11 in the

327 hippocampal PSD fraction of vGAT-Btbd11 KO mice (**Figure 5C**). As PV-INs displayed the highest level

328 of Btbd11 expression (based on RNA datasets, see **Figure 1D**) we decided to assess glutamatergic

329 synapse function within PV-INs from CON or vGAT-Btbd11 KO mice by measuring miniature excitatory

330 post synaptic potentials (mEPSCs) with whole-cell patch clamp recordings. We expressed tdTomato in

331 the visual cortex PV-INs in CON or vGAT-Btbd11 KO littermates using AAVs with PV-specific enhancers

332 (Vormstein-Schneider et al., 2020) to enable fluorescently guided recordings (**Figure 5D,E**). While the

333 amplitude remained unchanged between the conditions (**Figure 5F**), we observed a dramatic decrease

334 in the frequency of mEPSCs (**Figure 5G**). A frequency decrease could reflect fewer glutamatergic

335 synapses in PV-INs of vGAT-Btbd11 KO mice, or a decreased presynaptic release probability. We

336 measured the paired-pulse ratio (PPR) using electrical stimulation to explore presynaptic release

337 probabilities (**Figure 5H,I**). The PPR was comparable between groups, suggesting that presynaptic

338 release probabilities were not changed with Btbd11 knockout from INs (**Figure 5J**). Together, these data

339 show that Btbd11$^{F/F}$ mice are an effective tool to study Btbd11 KO and confirm the IN-specific nature of

340 Btbd11 expression. Furthermore, we find that Btbd11 KO leads to decreased glutamatergic recruitment

341 of PV-INs, likely though a postsynaptic mechanism.

Figure 5. Btbd11 KO reduces glutamatergic signaling in PV-INs.

(A) Northern blot to evaluate levels of Btbd11 mRNA in Btbd11$^{F/F}$ cultures transduced with AAV-GFP (left lane) or AAV-GFP-Cre (right lane) and harvested at DIV14. 10μg of RNA was loaded onto a gel and ethidium bromide staining was used to confirm equal loading of RNA. Locations of 18S and 28S ribosomal RNA are indicated with blue dots. (B) Western blots characterizing the levels of Btbd11 (top blot) and Psd-95 (lower blot, as a loading control) in primary cortical Btbd11$^{F/F}$ cultures transduced with AAV-GFP (left lanes) or AAV-GFP-Cre (right lanes). 12μg of protein was loaded from the PSD fraction (where Btbd11 is enriched). Cells were harvested at DIV12 and DIV14 (one sample per condition per timepoint). A black arrow indicates the band corresponding to Btbd11. (C) Western blots evaluating the levels of Btbd11 (top blot) and Psd-95 (lower blot, as a loading control) from the hippocampal PSD fraction of female control Btbd11$^{F/F}$ animals or vGAT:Btbd11$^{F/F}$ mice aged 3 months where Btbd11 is conditionally knocked out from INs. 20μg of protein was loaded. A black arrow indicates the band corresponding to Btbd11. (D) Schematic depicting the site of AAV-S5E2-tdTomato injection, used to visualize PV-INs in the V1 (left), with zoomed out (middle) and zoomed-in (right) merged image of DIC and mCherry fluorescence. (E) Example mEPSC traces recorded from V1 PV-INs in Btbd11$^{F/F}$ or vGAT:Btbd11$^{F/F}$ mice. (F and G) The mEPSC amplitude and frequency, respectively, of mEPSCs recorded from PV-INs from Btbd11$^{F/F}$ (black) animals or vGAT:Btbd11$^{F/F}$ (magenta) mice. Error bars display S.E.M. *** indicates p < 0.001. (H) DIC image showing the placement of the electrical stimulating electrode for paired pulse ratio (PPR) recordings. (I) Example traces used to calculate the PPR in Btbd11$^{F/F}$ or vGAT:Btbd11$^{F/F}$ mice. (J) PPR data recorded from PV-INs from Btbd11$^{F/F}$ (Black) or vGAT:Btbd11$^{F/F}$ (magenta) mice. Error bars display S.E.M.

14

Loss of Btbd11 impacts circuit function *in vitro* and *in vivo*

INs are well known to play a critical role in regulating the activity of neuronal circuits. Having found that vGAT-Btbd11 KO mice have reduced glutamatergic recruitment of PV-INs, we speculated that network properties might be abnormal following Btbd11 KO. To test this, we first returned to our *in vitro* cell culture system and prepared primary hippocampal cultures from P0 Btbd11$^{F/F}$ pups. We delivered GFP (CON) or GFP-Cre (KO) and jRGEGCO1 to cultures through AAV-transduction at DIV1-2 (**Figure 6A**). Spontaneous activity of the cultures was measured with live-cell imaging of the jRGECO1 signal to track Ca^{2+} dynamics. Large, and synchronous, Ca^{2+} transients were observed throughout the cultures (**Video S4,5**). We quantify these activity patterns in CON and KO cultures (**Figure 6B**). As expected for a dis-inhibited network, there was an increased frequency of Ca^{2+} transients in KO cultures (**Figure 6C**). Interestingly, the expression of PV protein was dramatically upregulated both in KO hippocampal cultures (observed with immunofluorescence; **Figure 6D,E**) and KO cortical cultures (observed with western blots; **Figure 6F,G**), potentially reflecting elevated activity since PV expression is regulated by activity of PV neurons (Donato et al., 2013).

Next, we assessed circuit function *in vivo* using CON and vGAT-Btbd11 KO mice. PV-IN function has been closely tied to the regulation of fast local field potential (LFP) oscillations in the 30-100Hz "gamma" frequency (Cardin et al., 2009; Mann et al., 2005; Sohal et al., 2009). A narrowband gamma oscillation ~55-65Hz can be induced in the visual cortex through presentation of a gray screen alone (Saleem et al., 2017). We exploited this straightforward assay to explore visually evoked gamma oscillations in the V1 of CON and vGAT-Btbd11 KO animals (**Figure 6H,I**). We implanted a tungsten electrode targeted to layer 4 of V1 as in (Cooke et al., 2015), and attached a metal bar to enable head-fixation of animals. After recovery from surgery, mice were handled and habituated to head restraint, then presented with either a black or gray screen (**Figure 6J**). As previously reported, we observed a narrowband gamma oscillation in the 55-65Hz range. Interestingly, we found that the gray/black screen ratio of both mean (**Figure 6K**) and peak (**Figure 6L**) 55-65 Hz activity was elevated in vGAT-Btbd11 KO animals compared to CONs indicating increased power in the narrowband gamma frequency. These data, *in vitro* and *in vivo*, argue that Btbd11 loss-of-function can impact the activity patterns of neuronal circuits, with important implications for their function in different states.

389

390 **Figure 6.** Loss of Btbd11 impacts circuit function *in vitro* and *in vivo.*
391 (A) Confocal live-cell image of primary cultured hippocampal neurons from Btbd11$^{F/F}$ mice transduced with AAV-
392 jRGECO1a (magenta) and AAV-GFP or AAV-GFP-Cre (green). The example image is with AAV-GFP-Cre. Scale
393 bar = 100μm. (B) Example traces for control (AAV-GFP, top) and knockout (AAV-GFP-Cre, bottom) cultures
394 showing the average Ca^{2+} activity across multiple neurons in one field of view over a 60s period. Red stars indicate
395 automatically identified peaks. (C) Quantification of large Ca^{2+} transients across multiple regions of interest and
396 coverslips from 3 independent batches of neurons. Control (AAV-GFP) data is shown in black and knockout (AAV-
397 GFP-Cre) data in magenta. *** indicates p <0.001. Error bars indicate S.E.M. (D) Confocal image showing
398 immunofluorescence of PV in DIV14 primary cultures hippocampal Btbd11$^{F/F}$ neurons transduced with AAV-GFP
399 (control, top) or AAV-GFP-Cre (knockout, bottom). Scale bar = 10μm. (E) Quantification of PV immunofluorescence
400 data with control data in black and knockout data in magenta. Error bars display S.E.M. (F) Western blot from the
401 cytosolic S2 fraction of DIV14 primary cultured cortical Btbd11$^{F/F}$ neurons transduced with AAV-GFP (control) or
402 AAV-GFP-Cre (knockout). Top blot shows levels of PV, and the bottom blot shows alpha-tubulin used as a loading
403 control. 30μg of lysate was run. (G) Quantification of western blot data evaluating levels of PV (normalized to alpha-
404 tubulin levels) with control data in black and knockout data in magenta. Error bars display S.E.M. (H) Schematic of
405 in vivo setup used to assess narrowband gamma oscillations in the V1 with presentation of a gray screen. (I)
406 Example spectrogram showing the power over time in the 0-80 Hz range from the V1 of a vGAT:Btbd11$^{F/F}$ mouse
407 presented with a gray screen. Note the pronounced activity in the 55-65 Hz range. (J) Power spectra for Btbd11$^{F/F}$
408 mice (n = 5, top; dark gray = dark screen, light gray = gray screen) and vGAT:Btbd11$^{F/F}$ mice (n = 6, bottom; light
409 magenta = dark screen, dark magenta gray = gray screen). Error bars indicate the S.E.M. (K and L) Quantification
410 of the mean or peak 55-65 Hz activity, respectively, presented as a ratio of gray screen/black screen. Error bars
411 display S.E.M. * indicates p < 0.05.
412

413 **Btbd11 KO mice are sensitized to challenge with an NMDA receptor antagonist**

414 Having observed that Btbd11 knockout can impact circuit activity, we wondered if vGAT-Btbd11

415 KO mice impacts animal behavior. We assessed the behavior of CON and vGAT-Btbd11 KO animals in

416 an open field to assess locomotor activity. Animals were run in the dark, with infrared beam breaks used

417 as a readout of activity (**Figure 7A**). No differences were observed in terms of the total beam breaks

418 (**Figure 7B**). We subsequently assessed short-term spatial memory using a spontaneous alternation

419 version of the Y-maze. We observed no difference between CON and vGAT-Btbd11 KO animals,

420 indicating that under basal conditions spatial short-term memory was intact (**Figure 7C**).

421 Genetic manipulations that impact glutamatergic synapses in INs often display altered sensitivity

422 to NMDA receptor antagonist challenge. For example, mice which lack NMDARs in PV-INs are more

423 sensitive to the effects of the NMDA receptor antagonist MK-801 (Bygrave et al., 2016). Since vGAT-

424 Btbd11-KO mice had reduced glutamatergic recruitment of PV-INs we speculated that they might be

425 predisposed to MK-801 challenge. Therefore, we administered CON and vGAT-Btbd11 KO mice with

426 MK-801 (0.2 mg kg^{-1}) or saline (as a vehicle) and measured their locomotor response in the open field

427 apparatus, this time in the light (**Figure 7D**). MK-801 administration led to a dramatic increase in

428 locomotor activity, however, this was particularly prominent in vGAT-Btbd11 KO mice, indicating a

429 increased sensitivity to the drug (**Figure 7E**). These data show that the underlying circuitry in mice which

430 lack Btbd11 in INs sensitizes them to subsequent NMDA receptor challenge.

431
432

Figure 7. Btbd11 KO mice are sensitized to challenge with an NMDA receptor antagonist.
(A) Locomotor activity of Btbd11$^{F/F}$ (black) and vGAT:Btbd11$^{F/F}$ (magenta) mice exploring a novel environment. Infrared beam breaks were used as a proxy of locomotor activity. Error bars indicate S.E.M. (B) Total beam breaks in the 90 min exploration period for Btbd11$^{F/F}$ (black) and vGAT:Btbd11$^{F/F}$ (magenta) animals. Error bars indicate S.E.M. (C) Spontaneous alternation of Btbd11$^{F/F}$ (black) and vGAT:Btbd11$^{F/F}$ (magenta) animals in a Y-maze test of short-term spatial memory. Error bars indicate S.E.M. (D) Locomotor activity of Btbd11$^{F/F}$ (black and gray) and vGAT:Btbd11$^{F/F}$ (light and dark magenta) mice in an open field arena following injection with either saline or MK-801 (0.2mg/kg). Infrared beam breaks were used as a proxy of locomotor activity. Error bars indicate S.E.M. (E) Quantification of the total infrared beam breaks in the 30-60-min period after injection in Btbd11$^{F/F}$ (black) and vGAT:Btbd11$^{F/F}$ (magenta) mice. * Indicates $p < 0.05$.

DISCUSSION

In this study we identify Btbd11 as a novel inPSD protein and characterize its basic properties and function using biochemistry, imaging, electrophysiology, and behavior.

Glutamatergic PSDs show cell-type-specific protein specializations

Using immunoisolation and proteomics we demonstrate that it is possible to identify inPSD specific proteins. To the best of our knowledge, this is the first attempt to uncover differences in PSD

18

450   composition between INs and ENs using proteomics. A similar method was used to examine differences

451   in PSDs from different subpopulations of ENs (Zhu et al., 2020), highlighting the usefulness of the

452   approach. Initially we focused our effort into a thorough characterizing of Btbd11. In future studies it will

453   be interesting to explore the other putative inPSD proteins (**Table S1**). Furthermore, by combining

454   proteomic with new methods such as *in vivo* proximity labeling (Branon et al., 2018; Uezu et al., 2016), it

455   should be possible to uncover yet more PSD protein specializations, including those that do not form

456   complexes with Psd-95 which would likely be missed by our screen.

457   **Btbd11 is localized exclusively to inPSDs in cortex and hippocampus**

458   Converging evidence shows that Btbd11 is expressed exclusively in INs within cortical and

459   hippocampal tissue, however, it is possible that in other brain regions this cell-type-specificity will be lost.

460   It is noteworthy that Btbd11 was previously identified as a reliable marker of cortical interneurons,

461   although no function or properties of Btbd11 were explored (Rossier et al., 2015). The subcellular

462   distribution of Btbd11 is highly targeted to glutamatergic synapses—via interactions with Btbd11's PBM.

463   Our yeast 2-hybrid screen indicates putative interacting proteins, including known synaptic proteins that

464   impact synapse function. It will be important to further characterize the interactome of Btbd11 to gain

465   further mechanistic insights into how it regulates glutamatergic synapses in INs.

466   **LLPS of Btbd11 with Psd-95**

467   We show that Btbd11 undergoes LLPS with Psd-95. LLPS is highly sensitive to protein

468   concentration, but since the PSD concentrates synaptic proteins, we expect the concentration of Btbd11

469   and Psd-95 to surpass a threshold to support biomolecular condensation at glutamatergic synapses in

470   INs. Thus far, difficulties in purifying full-length Btbd11 (which we find is necessary for LLPS properties)

471   have prevented *in vitro* studies to calculate the precise concentration of Btbd11 and Psd-95 required to

472   trigger LLPS. Phase separation at the PSD is likely ubiquitous among neuronal cell-types and has been

473   argued to underscore the assembly and stability of the PSD (Chen et al., 2020; Feng et al., 2019; Zeng

474   et al., 2016). It is tempting to speculate that Btbd11 can stabilize Psd-95 at the synapse through promoting

475   LLPS. If this was indeed the case it likely reflects a generalizable phenomenon, for which we have

476   identified a particular cell-type-specific specialization involving Btbd11 utilized by INs. LLPS of the iPSD

477   may play an even more critical role than it does at the ePSD as the iPSD is exposed on the dendritic

478   shaft and is not compartmentalized in spine-like protrusions thought to limit diffusion to and from the

479   synapse.

480   **Reduced glutamatergic recruitment in PV neurons of Btbd11 KO mice**

481   With whole-cell patch clamp recordings we observed a decrease in the mEPSC frequency in PV-

482   INs when Btbd11 was knocked out from INs. This phenotype is similar to that of IN-specific deletion of

483   ErbB4 or global knockout of Brevican, two proteins that are also enriched at glutamatergic synapses in

484   PV-INs (Favuzzi et al., 2017; del Pino et al., 2013). Because a measure of presynaptic release (PPR)

485   was unchanged with Btbd11 knockout, we expect that this mEPSC phenotype is a result of decreased

486   glutamatergic synapses within PV-INs. We expect this is a consequence of a destabilizing effect on Psd-

487   95 due to Btbd11 knockout, as we found that Btbd11 overexpression was able to stabilize Psd-95 at the

488   PSD of cultured INs. It will be interesting to test if other IN subtypes, such as those expressing

489   somatostatin, also receive reduced glutamatergic input. Furthermore, in subsequent studies it will be

490   interesting to elucidate if there is a time dependence of Btbd11 deletion, or if this phenotype is dependent

491   on gene deletion early in development (Cre switches on early in the vGAT^{Cre} line).

492   **Altered network properties and sensitivity to NMDA receptor challenge in Btbd11 KO mice**

493   In cultured Btbd11 knockout neurons we observed an increase in spontaneous Ca^{2+} transients,

494   consistent with a lack of inhibition in the cultures. Furthermore, we observed an exaggerated induced

495   gamma frequency oscillation *in vivo* when mice were presented with a gray screen. Because of the role

496   PV-INs have in regulating the firing of other neurons and supporting synchronous activity, we suspect

497   that altered activity of PV-INs—through loss of glutamatergic signaling—is responsible for these changes

498   in network properties. Behaviorally, we observed that IN-specific Btbd11 knockout mice are sensitized to

499   NMDA receptor antagonism with MK-801. Previous work has shown that INs could be preferentially

500   sensitive to NMDA receptor antagonism at certain doses (Homayoun and Moghaddam, 2007).

501   Furthermore, deletion of NMDA receptors from different populations of INs results in differential sensitivity

502   to MK-801 challenge (Belforte et al., 2010; Bygrave et al., 2016, 2019; Cardin et al., 2009). The increased

503   sensitivity vGAT-Btbd11 KO mice to MK-801 likely manifests because of their decreased number of

504   glutamatergic synapses in PV-INs. In future studies it will be interesting to test if other stressors, such as

505   post-weaning isolation (Belforte et al., 2010; Jiang et al., 2013) or reduced environmental enrichment

506   (Bygrave et al., 2019) have exaggerated effects on vGAT-Btbd11 KO mice compared to CON animals.

507   In summary, we reveal that Btbd11 as an IN-specific glutamatergic synaptic protein and show that

508   it plays an important role in regulating glutamatergic synapses in INs using biochemistry and *in vitro* live-

509   cell imaging experiments through to *in vivo* physiology and behavior. It will be important to uncover if

510   Btbd11—or other inPSD proteins—could be potential therapeutic targets for neurological disorders in

511   which GABAergic signaling is disrupted.

512

513   **ACKNOWLEDGEMENTS**

520 electron microscopy, Paul Worley for useful discussions and input on experimental design, and Tatiana
521 Boronina and Robert Cole for running and analyzing mass spectrometry data.
522

DECLARATION OF INTERESTS

527

REFERENCES

529 Alberti, S., and Dormann, D. (2019). Liquid–Liquid Phase Separation in Disease. Annu. Rev. Genet. *53*,
530 annurev-genet-112618-043527.
531
532 Belforte, J.E., Zsiros, V., Sklar, E.R., Jiang, Z., Yu, G., Li, Y., Quinlan, E.M., and Nakazawa, K. (2010).
533 Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes.
534 Nat. Neurosci. *13*, 76–83.
535
536 Branon, T.C., Bosch, J.A., Sanchez, A.D., Udeshi, N.D., Svinkina, T., Carr, S.A., Feldman, J.L.,
537 Perrimon, N., and Ting, A.Y. (2018). Efficient proximity labeling in living cells and organisms with
538 TurboID. Nat. Biotechnol. *36*, 880–898.
539
540 Bygrave, A.M., Masiulis, S., Nicholson, E., Berkemann, M., Barkus, C., Sprengel, R., Harrison, P.J.,
541 Kullmann, D.M., Bannerman, D.M., and Kätzel, D. (2016). Knockout of NMDA-receptors from
542 parvalbumin interneurons sensitizes to schizophrenia-related deficits induced by MK-801. Transl.
543 Psychiatry *6*, e778.
544
545 Bygrave, A.M., Masiulis, S., Kullmann, D.M., Bannerman, D.M., and Kätzel, D. (2019). Gene-
546 environment interaction in a conditional NMDAR-knockout model of schizophrenia. Front. Behav.
547 Neurosci. *12*, 1–6.
548
549 Cardin, J.A., Carlén, M., Meletis, K., Knoblich, U., Zhang, F., Deisseroth, K., Tsai, L.-H., and Moore,
550 C.I. (2009). Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature
551 *459*, 663–667.
552
553 Chang, M.C., Park, J.M., Pelkey, K.A., Grabenstatter, H.L., Xu, D., Linden, D.J., Sutula, T.P., McBain,
554 C.J., and Worley, P.F. (2010). Narp regulates homeostatic scaling of excitatory synapses on
555 parvalbumin-expressing interneurons. Nat. Neurosci. *13*, 1090–1097.
556
557 Chen, X., Wu, X., Wu, H., and Zhang, M. (2020). Phase separation at the synapse. Nat. Neurosci. *23*,
558 301–310.
559
560 Cooke, S.F., Komorowski, R.W., Kaplan, E.S., Gavornik, J.P., and Bear, M.F. (2015). Visual recognition
561 memory , manifested as long-term habituation , requires synaptic plasticity in V1. Nat. Neurosci. *18*.
562
563 Dimidschstein, J., Chen, Q., Tremblay, R., Rogers, S.L., Saldi, G.-A., Guo, L., Xu, Q., Liu, R., Lu, C.,
564 Chu, J., et al. (2016). A viral strategy for targeting and manipulating interneurons across vertebrate
565 species. Nat. Neurosci. *19*, 1743–1749.
566

567 Donato, F., Rompani, S.B., and Caroni, P. (2013). Parvalbumin-expressing basket-cell network
568 plasticity induced by experience regulates adult learning. Nature *504*, 272–276.
569
570 Fang, H., Bygrave, A.M., Roth, R.H., Johnson, R.C., and Huganir, R.L. (2021). An optimized
571 CRISPR/Cas9 approach for precise genome editing in neurons. Elife *10:e65202*, 1–25.
572
573 Favuzzi, E., Marques-Smith, A., Deogracias, R., Winterflood, C.M., Sánchez-Aguilera, A., Mantoan, L.,
574 Maeso, P., Fernandes, C., Ewers, H., and Rico, B. (2017). Activity-Dependent Gating of Parvalbumin
575 Interneuron Function by the Perineuronal Net Protein Brevican. Neuron *95*, 639-655.e10.
576
577 Feng, Z., Chen, X., Zeng, M., and Zhang, M. (2019). Phase separation as a mechanism for assembling
578 dynamic postsynaptic density signalling complexes. Curr. Opin. Neurobiol. *57*, 1–8.
579
580 Fernández, E., Collins, M.O., Uren, R.T., Kopanitsa, M. V., Komiyama, N.H., Croning, M.D.R.,
581 Zografos, L., Armstrong, J.D., Choudhary, J.S., and Grant, S.G.N. (2009). Targeted tandem affinity
582 purification of PSD-95 recovers core postsynaptic complexes and schizophrenia susceptibility proteins.
583 Mol. Syst. Biol. *5*.
584
585 Fortin, D. a., Tillo, S.E., Yang, G., Rah, J.-C.J.-C., Melander, J.B., Bai, S., Soler-Cedeno, O., Qin, M.,
586 Zemelman, B. V., Guo, C., et al. (2014). Live Imaging of Endogenous PSD-95 Using ENABLED: A
587 Conditional Strategy to Fluorescently Label Endogenous Proteins. J. Neurosci. *34*, 16698–16712.
588
589 Furlanis, E., Traunmüller, L., Fucile, G., and Scheiffele, P. (2019). Landscape of ribosome-engaged
590 transcript isoforms reveals extensive neuronal-cell-class-specific alternative splicing programs. Nat.
591 Neurosci. *22*, 1709–1717.
592
593 Geiger, J.R.P., Melcher, T., Koh, D.S., Sakmann, B., Seeburg, P.H., Jonas, P., and Monyer, H. (1995).
594 Relative abundance of subunit mRNAs determines gating and Ca2+ permeability of AMPA receptors in
595 principal neurons and interneurons in rat CNS. Neuron *15*, 193–204.
596
597 Homayoun, H., and Moghaddam, B. (2007). NMDA receptor hypofunction produces opposite effects on
598 prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. *27*, 11496–11500.
599
600 Hu, H., Gan, J., and Jonas, P. (2014). Interneurons. Fast-spiking, parvalbumin$^+$ GABAergic
601 interneurons: from cellular design to microcircuit function. Science *345*, 1255263.
602
603 Imamura, F., Maeda, S., Doi, T., and Fujiyoshi, Y. (2002). Ligand binding of the second PDZ domain
604 regulates clustering of PSD-95 with the Kv1.4 potassium channel. J. Biol. Chem. *277*, 3640–3646.
605
606 Jiang, Z., Rompala, G.R., Zhang, S., Cowell, R.M., and Nakazawa, K. (2013). Social isolation
607 exacerbates schizophrenia-like phenotypes via oxidative stress in cortical interneurons. Biol. Psychiatry
608 *73*, 1024–1034.
609
610 Keck, T., Scheuss, V., Jacobsen, R.I., Wierenga, C.J., Eysel, U.T., Bonhoeffer, T., and Hu, M. (2011).
611 Article Loss of Sensory Input Causes Rapid Structural Changes of Inhibitory Neurons in Adult Mouse
612 Visual Cortex. 869–882.
613
614 Kuhlman, S.J., Olivas, N.D., Tring, E., Ikrar, T., Xu, X., and Trachtenberg, J.T. (2013). A disinhibitory
615 microcircuit initiates critical-period plasticity in the visual cortex. Nature *501*, 543–546.
616
617 Lamsa, K.P., Heeroma, J.H., Somogyi, P., Rusakov, D. a, and Kullmann, D.M. (2007). Anti-Hebbian

long-term potentiation in the hippocampal feedback inhibitory circuit. Science *315*, 1262–1266.

Lewis, D. a, Hashimoto, T., and Volk, D.W. (2005). Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. *6*, 312–324.

Lisman, J.E., Coyle, J.T., Green, R.W., Javitt, D.C., Benes, F.M., Heckers, S., and Grace, A. a (2008). Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. *31*, 234–242.

Mann, E.O., Suckling, J.M., Hajos, N., Greenfield, S. a, and Paulsen, O. (2005). Perisomatic feedback inhibition underlies cholinergically induced fast network oscillations in the rat hippocampus in vitro. Neuron *45*, 105–117.

Marín, O. (2012). Interneuron dysfunction in psychiatric disorders. Nat. Rev. Neurosci. 107–120.

Matta, J. a, Pelkey, K. a, Craig, M.T., Chittajallu, R., Jeffries, B.W., and McBain, C.J. (2013). Developmental origin dictates interneuron AMPA and NMDA receptor subunit composition and plasticity. Nat. Neurosci. *16*, 1032–1041.

Melander, J.B., Nayebi, A., Jongbloets, B.C., Fortin, D.A., Qin, M., Ganguli, S., and Zhong, H. (2021). Distinct in vivo dynamics of excitatory synapses onto cortical pyramidal neurons and inhibitory interneurons. BioRxiv.

Molliex, A., Temirov, J., Lee, J., Coughlin, M., Kanagaraj, A.P., Kim, H.J., Mittag, T., and Taylor, J.P. (2015). Phase Separation by Low Complexity Domains Promotes Stress Granule Assembly and Drives Pathological Fibrillization. Cell *163*, 123–133.

Mosavi, L.K., Cammett, T.J., Desrosiers, D.C., and Peng, Z. (2004). The ankyrin repeat as molecular architecture for protein recognition. Protein Sci. *13*, 1435–1448.

del Pino, I., García-Frigola, C., Dehorter, N., Brotons-Mas, J.R., Alvarez-Salvado, E., Martínez de Lagrán, M., Ciceri, G., Gabaldón, M.V., Moratal, D., Dierssen, M., et al. (2013). Erbb4 Deletion from Fast-Spiking Interneurons Causes Schizophrenia-like Phenotypes. Neuron *79*, 1152–1168.

Rossier, J., Bernard, A., Cabungcal, J.H., Perrenoud, Q., Savoye, A., Gallopin, T., Hawrylycz, M., Cuénod, M., Do, K., Urban, A., et al. (2015). Cortical fast-spiking parvalbumin interneurons enwrapped in the perineuronal net express the metallopeptidases Adamts8, Adamts15 and Neprilysin. Mol. Psychiatry *20*, 154–161.

Ryder, E., Gleeson, D., Sethi, D., Vyas, S., Miklejewska, E., Dalvi, P., Habib, B., Cook, R., Hardy, M., Jhaveri, K., et al. (2013). Molecular characterization of mutant mouse strains generated from the EUCOMM/KOMP-CSD ES cell resource. Mamm. Genome *24*, 286–294.

Saleem, A.B., Lien, A.D., Krumin, M., Haider, B., Rosón, M.R., Ayaz, A., Reinhold, K., Busse, L., Carandini, M., Harris, K.D., et al. (2017). Subcortical Source and Modulation of the Narrowband Gamma Oscillation in Mouse Visual Cortex. Neuron *93*, 315–322.

Sancho, L., Bloodgood, B.L., Sancho, L., and Bloodgood, B.L. (2018). Functional Distinctions between Spine and Dendritic Synapses Made onto Parvalbumin-Positive Interneurons in Mouse Cortex Article Functional Distinctions between Spine and Dendritic Synapses Made onto Parvalbumin-Positive Interneurons in Mouse Cortex. CellReports *24*, 2075–2087.

669
670 Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S.,
671 Rueden, C., Saalfeld, S., Schmid, B., et al. (2012). Fiji: An open-source platform for biological-image
672 analysis. Nat. Methods *9*, 676–682.
673
674 Senior, A.W., Evans, R., Jumper, J., Kirkpatrick, J., Sifre, L., Green, T., Qin, C., Žídek, A., Nelson,
675 A.W.R., Bridgland, A., et al. (2020). Improved protein structure prediction using potentials from deep
676 learning. Nature *577*, 706–710.
677
678 Sohal, V.S., Zhang, F., Yizhar, O., and Deisseroth, K. (2009). Parvalbumin neurons and gamma
679 rhythms enhance cortical circuit performance. Nature *459*, 698–702.
680
681 Tasic, B., Menon, V., Nguyen, T.N., Kim, T.K., Jarsky, T., Yao, Z., Levi, B., Gray, L.T., Sorensen, S.A.,
682 Dolbeare, T., et al. (2016). Adult mouse cortical cell taxonomy revealed by single cell transcriptomics.
683 Nat Neurosci *19*, 335–345.
684
685 Uezu, A., Kanak, D.J., Bradshaw, T.W.A., Catavero, C.M., Alain, C., Weinberg, R.J., and Soderling,
686 S.H. (2016). Identification of an elaborate complex mediating postsynaptic inhibition. Science (80-.).
687 *353*, 960–962.
688
689 Uversky, V.N. (2017). Protein intrinsic disorder-based liquid–liquid phase transitions in biological
690 systems: Complex coacervates and membrane-less organelles. Adv. Colloid Interface Sci. *239*, 97–
691 114.
692
693 Vormstein-Schneider, D., Lin, J.D., Pelkey, K.A., Chittajallu, R., Guo, B., Arias-Garcia, M.A., Allaway,
694 K., Sakopoulos, S., Schneider, G., Stevenson, O., et al. (2020). Viral manipulation of functionally
695 distinct interneurons in mice, non-human primates and humans. Nat. Neurosci. *23*, 1629–1636.
696
697 Willems, J., de Jong, A.P.H., Scheefhals, N., Mertens, E., Catsburg, L.A.E., Poorthuis, R.B., de Winter,
698 F., Verhaagen, J., Meye, F.J., and MacGillavry, H.D. (2020). ORANGE: A CRISPR/Cas9-based
699 genome editing toolbox for epitope tagging of endogenous proteins in neurons. PLoS Biol. *18*,
700 e3000665.
701
702 Zeng, M., Shang, Y., Araki, Y., Guo, T., Huganir, R.L., and Zhang, M. (2016). Phase Transition in
703 Postsynaptic Densities Underlies Formation of Synaptic Complexes and Synaptic Plasticity. Cell *166*,
704 1163-1175.e12.
705
706 Zeng, M., Díaz-Alonso, J., Ye, F., Chen, X., Xu, J., Ji, Z., Nicoll, R.A., and Zhang, M. (2019). Phase
707 Separation-Mediated TARP/MAGUK Complex Condensation and AMPA Receptor Synaptic
708 Transmission. Neuron 529–543.
709
710 Zhu, F., Collins, M.O., Harmse, J., Choudhary, J.S., Grant, S.G.N., and Komiyama, N.H. (2020). Cell-
711 type-specific visualisation and biochemical isolation of endogenous synaptic proteins in mice. Eur. J.
712 Neurosci. *51*, 793–805.
713
714

SUPPLEMENTARY FIGURES

Figure S1. Validation of Btbd11 antibody, *related to Figure 1*
Western blot using lysate from HEK cell transfected with GFP-Btbd11 or non-transfected cells. Blots were probed with antibodies against Btbd11 (magenta) or GFP (green). The merged image shows the overlap of the bands identified with each antibody.

**Figure S2.** Yeast 2-hybrid screen identifies putative Btbd11 interaction partners, *related to Figure 2*
Schematic depiction of results from the yeast two-hybrid screen with the BTB domain or C-terminal portion of Btbd11 containing the PBM.

25

Figure S3. Liquid-liquid phase separation of Btbd11, *related to Figure 3*

(A and B) Proportion of HEK cells which contain fibril-like assemblies or droplets, respectively, when GFP-Btbd11 or GFP-Btbd11ΔPBM is expressed with or without Psd-95-mCherry. (C) Confocal image of HEK cells expressing GFP-5XANK-BTB (green), Psd-95-mCherry (magenta) and azurite (blue). Scale bar indicates 10μm. The white boxed area is enlarged on the right. The yellow dotted line indicates where a line-scan was evaluated. (D) Line scan showing signal intensity of GFP-5XANK-BTB (green) and Psd-95-mCherry (magenta). (E) FRAP of a mCherry-5XANK-BTB (magenta) and Psd-95-GFP (green) puncta with a composite image shown in the upper panels and just mCherry-5XANK-BTB shown on the bottom. Scale bar = 1μm. Note the lack of mCherry-5XANK-BTB signal recovery.

Figure S4. FRAP of Psd-95 in excitatory neurons, *related to Figure 4*

(A) Live-cell confocal imaging and FRAP of Psd-95-mCherry (magenta) in a putative interneuron (IN, identified with mDlx-Azurite) or excitatory neuron (EN, identified by the presence of dendritic spines with an Azurite cell-fill). The lower panels show FRAP of the individual puncta labeled in the upper panels with a white arrow. Respective scale bars are indicted at the bottom left of each image. (B) Quantification of Psd-95-mCherry FRAP in ENs (black) or INs (magenta). Error bars display S.E.M. (C) Quantification of the estimated recovery maximum from an exponential fit of the FRAP data for each bleached punctum. EN data is shown in black and IN data is in magenta. Error bars display S.E.M.

(D) Quantification of Psd-95-mCherry FRAP in ENs alone (black) or with overexpression of Btbd11 (magenta). Error bars display S.E.M. (E) Quantification of the estimated recovery maximum from an exponential fit of the FRAP data for each bleached punctum. EN control data is shown in black and EN data with Btbd11 overexpression is in magenta. Error bars display S.E.M. Note the EN data without Btbd11 in panel (B) is the same as the control data presented in panel (D).

A
Cortex p22 Northen blot

B
Hippocampus p22 Western blot

Figure S5. Characterization of Btbd11 Gene Trap mice, *related to Figure 5*
(A) Northern blots to assess the levels of Btbd11 mRNA in the cortex of postnatal day 22 Btbd11 wildtype (WT) or homozygous Btbd11 Gene Trap (GT) animals. Either 10μg or 20μg of mRNA was loaded. A blue dot indicates the location of 18S and 28S ribosomal RNA. (B) Western blots to assess the level of Btbd11 in the hippocampus of Btbd11 wildtype (WT) or homozygous Btbd11 Gene Trap (GT) animals. 10μg of the PSD fraction was run, and membranes were probed with an antibody for Btbd11. A black arrow indicates the band corresponding to Btbd11. On the right 20μg of WT cortical PSD fraction was run to ensure that endogenous Btbd11 could be detected.

Figure S6. Electrode placement reconstructions, *related to Figure 6*
Reconstructions of estimated electrode positioning based on electrolytic lesions. Black dots = Btbd11$^{F/F}$ and magenta dots = vGAT:Btbd11$^{F/F}$ animals, respectively. AP = anterior/posterior location relative to bregma. Note: there are two vGAT:Btbd11$^{F/F}$ with overlapping estimated lesion sites in the AP: -4.04 image.

776 **SUPPLEMENTARY TABLES**

inPSD hits with vGAT/CaMKII ratio with value > mean + 2x standard deviation		
Accession	**Description**	**log norm ratio (vGAT/CaMKII)**
NP_082985.2	ankyrin repeat and BTB/POZ domain-containing protein BTBD11 isoform 1 [Mus musculus]	3.37
NP_058017.1	stress-induced-phosphoprotein 1 [Mus musculus]	2.41
XP_006534552.1	PREDICTED: myosin-10 isoform X1 [Mus musculus]	2.23
NP_076288.1	protein O-GlcNAcase [Mus musculus]	2.08
XP_006515861.1	PREDICTED: TNF receptor-associated factor 3 isoform X1 [Mus musculus]	2.05
XP_006498025.1	PREDICTED: E3 ubiquitin-protein ligase LRSAM1 isoform X1 [Mus musculus]	2.02
XP_006538016.1	PREDICTED: F-box/LRR-repeat protein 4 isoform X1 [Mus musculus]	2.00
XP_017175463.1	PREDICTED: fatty-acid amide hydrolase 1 isoform X1 [Mus musculus]	1.93
XP_006527892.1	PREDICTED: glycerol kinase isoform X1 [Mus musculus]	1.92
NP_659136.1	palmitoyltransferase ZDHHC5 [Mus musculus]	1.89
XP_017171979.1	PREDICTED: oxidation resistance protein 1 isoform X1 [Mus musculus]	1.88
XP_006511788.1	PREDICTED: E3 ubiquitin-protein ligase ARIH2 isoform X1 [Mus musculus]	1.87
NP_085041.1	E3 ubiquitin-protein ligase RNF34 [Mus musculus]	1.86
XP_006519125.1	PREDICTED: E3 ubiquitin-protein ligase RNF31 isoform X1 [Mus musculus]	1.83
XP_006537872.1	PREDICTED: PHD finger protein 24 isoform X1 [Mus musculus]	1.75
NP_033750.1	a disintegrin and metallopeptidase domain 4 precursor [Mus musculus]	1.72
XP_011249102.1	PREDICTED: glutamate receptor ionotropic, NMDA 2D isoform X1 [Mus musculus]	1.68
XP_006533949.1	PREDICTED: mitochondrial Rho GTPase 1 isoform X1 [Mus musculus]	1.65
NP_035234.1	protein kinase C epsilon type [Mus musculus]	1.64
XP_006526184.1	PREDICTED: E3 ubiquitin-protein ligase RNF14 isoform X1 [Mus musculus]	1.62
XP_006516266.1	PREDICTED: WD repeat-containing protein 20 isoform X1 [Mus musculus]	1.62
NP_033534.2	vesicular inhibitory amino acid transporter [Mus musculus]	1.60

777

778 **Table S1.** Mass spectrometry results, *related to Figure 1*
779 Table of inPSD candidates identified in the cell type-specific Psd-95-GFP immunoisolation experiment. Proteins
780 were quantified with label-free quantification and then normalized to levels of Psd-95. Then the vGAT/CaMKII ratio
781 was calculated to identify putative proteins enriched at the PSD of inhibitory interneurons.

782

783

784

785

786

Main Figures	Test	Test statistic(s)	P-value
Figure 1K	Kolmogorov-Smirnov test (Puncta-to-puncta distance)	Kolmogorov-Smirnov D = 0.7170	<0.0001
Figure 2G	One-way ANONA (GST pull-down)	F (2,6) = 514.0	<0.0001
	Dunnett's multiple comparisons	WT vs. Btbd11ΔPBM; Mean Diff. = 90.05	<0.0001
	Dunnett's multiple comparisons	WT vs. GST; Mean Diff. = 99.91	<0.0001
Figure 2I	One-way ANONA (GST pull-down)	F (4,10) = 44.63	<0.0001
	Dunnett's multiple comparisons	WT vs. dPDZ1,2; Mean Diff. = 75.17	0.0001
	Dunnett's multiple comparisons	WT vs. dPDZ3; Mean Diff. = -10.35	0.7386
	Dunnett's multiple comparisons	WT vs. dPDZ1,2,3; Mean Diff. = 80.50	<0.0001
	Dunnett's multiple comparisons	WT vs. GST (no Btbd11); Mean Diff. = 99.90	<0.0001
Figure 4I	Repeated measures ANOVA (FRAP)		
	Time vs. Condition (+/- Btbd11)	F (4,400) = 0.3815	0.8219
	Time	F (4,400) = 2.693	0.0307
	Condition (+/- Btbd11)	(1,100) = 5.755	0.0183
Figure 4J	Unpaired T-test (FRAP vMAX)	t=2.417, df=100	0.0175
Figure 5F	Unpaired T-test (mEPSC amplitude)	t=0.7729, df=23	0.4474
Figure 5G	Unpaired T-test (mEPSC frequency)	t=4.503, df=23	0.0002
Figure 5J	Unpaired T-test (PPR)	t=0.7390, df=14	0.4721
Figure 6C	Unpaired T-test (Spontaneous Ca^{2+} transients)	t=5.763, df=51	<0.0001
Figure 6E	Unpaired T-test (PV immunofluorescence)	t=7.388, df=114	<0.0001
Figure 6G	Unpaired T-test (PV western blot)	t=4.617, df=12	0.0006
Figure 6K	Unpaired T-test (Ratio of mean 55-65Hz)	t=2.797, df=9	0.0208
Figure 6L	Unpaired T-test (Ratio of peak 55-65Hz)	t=2.969, df=9	0.0157
Figure 7A	Repeated measures ANOVA (Locomotor activity)		
	Time vs. Genotype	F (17, 357) = 1.622	0.0565
	Time	F (7.365, 154.7) = 35.12	<0.0001
	Genotype	F (1, 21) = 0.02106	0.8860
Figure 7B	Unpaired T-test (total beam breaks)	t=0.1451, df=21	0.8860
Figure 7C	Unpaired T-test (spontaneous alternation)	t=1.469, df=21	0.1567
Figure 7E	Two-way ANOVA (MK-801 induced locomotor activity)		
	Drug vs. Genotype	F (1, 14) = 4.875	0.0444
	Drug	F (1, 14) = 42.84	<0.0001
	Genotype	F (1, 14) = 7.815	0.0143
	Šídák's multiple comparisons test (Con vs. knockout under vehicle condition)	Predicted (LS) mean diff. = -168.3	0.9697
	Šídák's multiple comparisons test (Con vs. knockout under MK-801 condition)	Predicted (LS) mean diff. = -2663	0.0031
Supplementary Figures	**Test**	**Test statistic(s)**	**P-value**
Figure S4B	Repeated measures ANOVA (FRAP INs vs. ENs)		
	Time vs. Condition (EN vs. IN)	F (4, 340) = 2.825	0.0249
	Time	F (4, 340) = 1.832	0.1222
	Condition (EN vs. IN)	F (1, 85) = 0.04326	0.8357
Figure S4C	Unpaired T-test (FRAP vMAX INs vs. ENs)	t=0.5684, df=85	0.5713
Figure S4D	Repeated measures ANOVA (FRAP in ENs)		
	Time vs. Condition (+/- Btbd11)	F (4, 216) = 1.572	0.1829
	Time	F (4, 216) = 3.272	0.0125
	Condition (+/- Btbd11)	F (1, 54) = 0.8301	0.3663
Figure S4E	Unpaired T-test (FRAP vMAX +/- Btbd11 within ENs)	t=0.7092, df=54	0.4813

787

788 **Table S2.** Details of statistical tests run, *related to Figures 2 and 4-7*
789 Table with statistical details for all tests performed.
790

791

VIDEO TITLES

Video S1
Alpha Fold prediction of Btbd11 structure. Based on UniProt annotations and the recognition of a putative PDZ binding motif (PBM) portions of the protein are shaded as follows: red = disordered, gray = ankyrin repeats (Ank), blue = BTB domain (BTB), magenta = PDM.

Video S2
Time-lapse of two GFP-Btbd11 (green) and Psd-95-mCherry (magenta) puncta fusing over time. The cell also contains an azurite cell-fill (blue). This is the same data presented in **Figure 3K**.

Video S3
Longitudinal live-cell imaging of a hippocampal neuron expressing an Azurite cell-fill (Blue) and GFP-Btbd11 (Green). A portion of a GFP-Btbd11 fibril is bleached. Note the lack of fluorescence recovery.

Video S4
Live cell imaging of jRGECO1a in control cultures (Btbd11$^{F/F}$ with AAV-GFP). Note the synchronous Ca^{2+} transients.

Video S5
Live cell imaging of jRGECO1a in Btbd11 knockout cultures (Btbd11$^{F/F}$ with AAV-GFP-Cre). Note that the synchronous Ca^{2+} transients appear more frequent than in control conditions (**Video S4**).

814 **METHODS**

815 **Animal care**

816 All animals were treated in accordance with the Johns Hopkins University Animal Care and Use

817 Committee guidelines.

818 **GFP-immunoisolation**

819 Cortex and hippocampus from 1 CaMKII:Psd-95-GFP and 4 vGAT:Psd-95-GFP animals were collected

820 from male mice aged 11-12 weeks. Brain tissue was homogenized in 8ml of ice-cold lysis buffer (1%

821 DOC, 50mM Tris (pH9), 50mM NaF, 20μM $ZnCl_2$, 1mM Na_3VO_4) with the addition of Pefabloc SC

822 (Roche), Okadaic acid (200nM) and a protease inhibitor cocktail (Roche Complete) with a Dounce

823 homogenizer and solubilized for 1 hour rotating at 4°C. Samples were then clarified with spins at 17,000g

824 and 50,000g each for 30min and at 4°C. Further lysis buffer was added so that GFP-immunoisolation

825 experiments were set up in 10ml total volume. For each sample 50μl of pre-washed GFP-TRAP agarose

826 beads (Chromotek) was added and incubated with rotation overnight at 4°C. Beads were washed x6 with

827 ice-cold lysis buffer (with same inhibitors as before) using spin-filter columns (spin 1500g for 1 minute).

828 Samples were eluted with 1% SDS containing 2.5% beta-mercaptoethanol. The vGAT samples were

829 serially eluted to increase the concentration of eluant (since the abundance of Psd-95-GFP is much lower

830 in the vGAT:Psd-95-GFP mice). Samples were then subject to mass spectrometry.

831 Note: the same pull-down procedure was followed to get samples for western blots (**Figure 1C**), except

832 5x vGAT:Psd95-GFP mice were pooled.

833 **Mass spectrometry**

834 GFP-immunoisolation samples (see above) were reduced with DTT, alkylated with IAA and

835 TCA/Acetone precipitated with x8 volume overnight at 37°C. Samples were then re-constituted in 12uL

836 500mM TEAB, 48uL water and 25ng/uL trypsin/LysC added. Samples were proteolyzed at 37°C

837 overnight. Peptides were desalted on Qasis U-HLB plates, eluted with 60% acetonitrile/0.1%TFA, and

838 dried. Desalted peptides, 10% and 20% were analyzed by nano-LC/MS/MS on QExactive Plus at

839 resolution 140K on precursor and 35K on fragment, using 85min gradient from 2% acetonitrile/0.1%

840 formic acid to 98% acetonitrile/0.1% formic acid. Injected peptides showed abundant base peak

841 chromatographs. Database search: FilesRC option was applied and MSMS spectra were searched with

842 Mascot 6.1 via Proteome Discovere 2.3 against RefSeq2017_83_mouse and a small database with

843 added enzymes, bovine serum albumin (our standard). Mass tolerance 4ppm for precursor, 0.01Da for

844 fragment variable modifications: carbamidomethylation on Cys, oxidation on M, deamidation NQ.

845 Peptides validated with Percolator. Mascot .dat files compiled in Scaffold. Note: just the 20% samples

846 were used for analysis. Label-free quantification was performed, and protein abundances were

847 normalized to the abundance of Psd-95. The ratio of vGAT/CaMKII abundance was then calculated to

33

848   identify putative inPSD proteins (plotted in **Figure 1B**). From the ratio data, proteins with ratios greater

849   than the mean + 2X the standard deviation were classified as putative inPSD candidates (**Table S1**).

850   **Western blots**

851   Samples in Laemmli Buffer were heated to 60°C for 15 minutes prior to running western blots. Depending

852   on target protein Mw, precast 4-12% or 8% Bis-Tris gels were used (Thermo Fisher Scientific) with

853   NuPAGE MOPS SDS running buffer (Thermo Fisher Scientific). Proteins were transferred to

854   nitrocellulose membrane (GE Healthcare) and blocked for 1 hour with Odyssey Blocking Buffer (Li-COR

855   bioscience) before probing with primary antibodies (see below) overnight at 4°C or at room temperature

856   for 1-2 hours. Antibodies were made up in TBS supplemented with 3% BSA and 0.1% Tween-20. Blots

857   were washes with TBS with 0.1% Tween-20 (TBST) 4x and incubated with secondary antibodies (all

858   fluorescently conjugated with 680 or 800nm dyes and used at 1:10000 and from Li-COR bioscience)

859   made up in TBS supplemented with 3% BSA and 0.1% Tween-20 and 0.02% SDS for 1 hour at room

860   temp. Blots were washed 4x in TBST and imaged on a Li-COR scanner. Bands were quantified in Image

861   Studio (Li-COR bioscience). *Primary antibodies used:* Tanaka anti dsRED (Living colors, rabbit

862   polyclonal, 1:1000)*,* Santa Cruz anti -GFP (B2, IgG2$_a$, 1:2000)*,* homemade anti-Btbd11 (rabbit polyclonal,

863   1:500)*,* Neuromab anti-Psd-95 (K28/74 mouse IgG$_1$, 1:5000)*,* Sigma anti-GST (GST-2, mouse IgG2$_B$,

864   1:5000)*,* Swant anti-Parvalbumin (PV27, rabbit polyclonal, 1:5000), Santa Cruz anti-alpha-tubulin (B-7,

865   mouse IgG2$_a$, 1:5000).

866   **Immunofluorescence**

867   Neurons were rinsed 1X with PBS at room temperature and then fixed for 15 minutes at room temperature

868   with 4% paraformaldehyde (Electron Microscopy Sciences) made up in PBS and supplemented with 4%

869   sucrose. For certain experiments (**Figure 1G**) this fixation step was replaced with a 20-minute fixation in

870   methanol at -20°C. In other instances, to promote Gad-67 and Psd-95 immunofluorescence, cells were

871   subject to a 90s methanol wash (-20°C) following the paraformaldehyde fixation described above. Cells

872   were washed 4x with PBS and incubated in primary antibodies (see below) in a pH 7.4 gelatin buffer (30

873   mM phosphate buffer, 0.2% gelatin, 0.3% Triton X-100, and 0.25M NaCl) overnight at 4°C. Cells were

874   washed 4x with PBS and then incubated with secondary antibodies in the same GDB buffer for 1 hour at

875   room temperature. All 488, 568 and 647 secondary antibodies were raised in goat, Alexa Fluor

876   conjugated, used at 1:500 and purchased from Thermo Fisher Scientific. All 405 conjugated antibodies

877   were raised in goat, DyLight 405 conjugated, used at 1:500, and purchased from Jackson Immuno

878   Research Laboratories. Cells were washed 4x in PBS, briefly rinsed in distilled water and mounted on

879   slides with PermaFluor mounting media (Thermo Fisher Scientific). Slides were stored in the dark at 4°C.

880   *Primary antibodies used:* Abcam anti-GFP (ab13970, chicken, 1:2000)*,* Neuromab anti-Psd-95 (K28/43,

881   mouse IgG2$_a$, 1:500)*,* homemade anti-Btbd11 (rabbit polyclonal, 1:100)*,* Tanaka anti dsRED (Living

882 colors, rabbit polyclonal, 1:1000), Santa Cruz anti-Gad-67 (F-6, mouse IgG_3, 1:100), Swant anti-

883 parvalbumin (Clone 235, mouse, IgG_1, 1:1000), Synaptic Systems anti-Gephyrin (147 011, mouse, IgG_1,

884 1:500).

Yeast two-hybrid experiments

886 Different combinations of pDBLeu-Btbd11-C-terminus (consisting of the terminal 58 or 54 amino acids of

887 Btbd11 for Btbd11 and Btbd11ΔPBM, respectively) and pPC86 -PSD95 PDZ constructs were co-

888 transformed into PJ69 yeast cells and bait/prey pairs were selected for by growth on -Leu, Trp media at

889 30°C. Btbd11-PSD95 interactions were then tested by the ability of the different yeast bait/prey

890 combinations to grow on -Leu, Trp, His media.

891 To identify putative Btbd11 interaction partners the BTB domain of Btbd11 or the C-terminal region of

892 Btbd11 were cloned into pDBLeu and used as baits in yeast 2-hybrid screens with a rat hippocampal

893 library. Plasmids from yeast clones that could grow on -Leu,Trp, His, Ade media were rescued and

894 analyzed by sequencing.

Cell-culture

896 *HEK cells:*

897 HEK cells were grown on 10cm plates (for biochemistry) or on collagen (Advanced Biomatrix) coated

898 glass coverslips in 12-well plates (for immunofluorescence and live-cell imaging) in DMEM (Gibco)

899 supplemented with 10% Fetal Bovine Serum (Hyclone) and Penicillin-Streptomycin antibiotics (100 U/ml,

900 Thermo Fisher Scientific). For biochemistry (GST-Pulldown experiments) HEK cells were transfected via

901 Calcium Phosphate precipitation. For immunofluorescence and live-cell imaging experiments HEK cells

902 were transfected with Lipofectamine 2000 (Invitrogen).

903 *Primary cultured rat neurons:*

904 Timed pregnant Sprague-Dawley rats were purchased (ENVIGO) and dissected at embryonic day 18.

905 Dissection media (to make 1L) consists of 50 ml 10x HBSS (Gibco), 5 ml Penicillin-Streptomycin (Thermo

906 Fisher Scientific), 5 ml pyruvate (Gibco), 5 ml Hepes (Gibco) 10 mM final, 15 ml of 1M Glucose stock 30

907 mM final and 420 ml Mill-Q water. Cortical cells were plated onto glass coverslips coated with Poly-L-

908 Lysine hydrobromide (Sigma) at a density of 250K/well (of a 12-well plate) and grown in Neurobasal Plus

909 Medium (Gibco) supplemented with 2% B-27 Plus (Gibco), 2mM Glutamax (Thermo Fisher Scientific),

910 Penicillin-Streptomycin (100U/ml, Thermo Fisher Scientific), and 5% horse serum (Hyclone).

911 Hippocampal cells were plated at a density of 100K/well (of a 12-well plate) in the same manner except

912 with standard Neurobasal Medium and standard B27. For hippocampal cultures, cells were swapped to

913 serum-free media (as above but lacking horse serum) at DIV1 and subsequently fed once a week with

914 serum-free media. For cortical neurons, cells were fed with media containing 1% horse serum and FdU

915   (Sigma) at DIV4, then subsequently fed twice per week with serum free media (Neurobasal Plus Medium

916   and B27 Plus).

917   *Primary cultured mouse neurons:*

918   P0 Btbd11$^{F/F}$ pups were dissected and plated as above except 5% fetal bovine serum was used in place

919   of horse serum, and that Neurobasal Plus Medium and B27 Plus supplement was used for both

920   hippocampal and cortical cultures. Hippocampal neurons were plated onto Poly-L-Lysine coated

921   coverslips at a density of 200K/well (of a 12-well plate) and cortical neurons were plated at a density of

922   6.5-7M cells per 10cm plate (also Poly-L-Lysine coated. Cells were fed twice a week with serum free

923   media. AAVs were added to cultures at DIV1 or DIV2. AAV.CMV.PI.EGFP.WPRE.bGH (Serotype 2/9;

924   titer ≥ 1×10^{13} vg/mL), AAV.CMV.HI.eGFP-Cre.WPRE.SV40 (Serotype 2/9; titer ≥ 1×10^{13} vg/mL) and

925   AAV.Syn.NES-jRGECO1a.WPRE.SV40 (Serotype 2/9; titer ≥ 1×10^{13} vg/mL) viruses were purchased

926   from Addgene.

927   **PSD preparation**

928   Btbd11$^{F/F}$ primary cultured cortical neurons (1x10cm plate per condition) were collected by plate

929   scraping, or one hippocampus (per Gene Trap, vGAT:Btbd11$^{F/F}$ or Btbd11$^{F/F}$ control animal) was

930   dissected, and then homogenized by passage through a 26g needle, 12 times, in homogenization

931   buffer (320mM sucrose, 5mM sodium pyrophosphate, 1mM EDTA, 10mM HEPES pH 7.4, 200nM

932   okadaic acid, protease inhibitor cocktail (Roche)). The homogenate was centrifuged at 800g for 10

933   minutes at 4°C to yield the P1 and S1 fractions. S1 was further centrifuged at 17,000g for 20 mins at

934   4°C to yield P2 and S2 fractions. P2 was resuspended in milliQ water, adjusted to 4mM HEPES pH 7.4

935   from a 1M HEPES stock solution, and incubated with agitation at 4°C for 30 mins. The resuspended P2

936   was centrifuged at 25,000g for 20 minutes at 4°C to yield LP1 and LS2. LP1 was resuspended in 50mM

937   HEPES pH 7.4, then mixed with an equal volume of 1% triton X-100 and incubated with agitation at 4°C

938   for 15 minutes. The PSD fraction was generated by centrifugation at 32,000xg for 20 minutes at 4°C.

939   The final PSD pellet was resuspended in 1x RIPA buffer. Protein quantification was performed via

940   Bradford assay and samples made up in Laemmli Buffer containing 5% Beta-mercaptoethanol and

941   frozen.

942   **GST-pulldown experiments**

943   HEK cells (transfected via Ca^{2+} phosphate precipitation) grown to confluence on a 10cm plate were

944   washed 1X with PBS at room temp and then lysed in ice cold lysis buffer (1X Tris Buffered Saline, 1%

945   NP-40, 10mM NaPPi, 10mM NaF, 200nM okadaic acid, 1mM Na$_3$VO$_4$ and a home-made protease

946   inhibitor cocktail). Cells were scraped from the plate and lysed by rotation for 20 mins at 4°C. Lysates

947   were centrifuged at 17,000g for 15 minutes and the supernatant retained. 20μl of supernatant was kept

948   as 2% INPUT. 30μl of pre-washed Glutathione Sepharose 4B bead slurry (GE Healthcare) was added

36

949   to each sample and incubated with rotation for 2-hours at 4°C. Beads were washed in spin columns 5X

950   with lysis buffer and then eluted with 30-40ul of Laemmli Buffer containing 5% Beta-mercaptoethanol

951   and frozen or run immediately on western blots.

952   **Confocal microscopy and image analysis**

953   All confocal imaged was conducted with a Zeiss LSM 880 microscope. Neurons and HEK cells were

954   imaged in 37°C pH 7.4 ACSF (120mM NaCl, 5 mM KCl, 10mM Hepes, 10mM glucose, 2mM $CaCl_2$ and

955   1mM $MgCl_2$) in a humidity-controlled chamber. For FRAP experiments (neuron and HEK), the laser power

956   and repetitions needed for successful bleaching was optimized for each experiment, and then kept

957   consistent. Imaged were collected with oil-immersive 40x or 63x objectives, except for the Ca^{2+} imaging

958   experiments in mouse neurons, which was collected using a 10x air objective.

959   *Analysis of FRAP data:*

960   For FRAP experiments in neurons time-series Z-stacks were acquired with two timepoints acquired

961   before photobleaching. For each dendritic region at least 5 putative synaptic puncta (Psd-95-mCherry

962   puncta) were bleached, ensuring that there were several puncta in the field of view that were not

963   bleached. Images were analyzed in FIJI. Maximum image projections were generated for the timeseries,

964   and a median filter was applied to all channels (1-pixel) and the Azurite cell-fill channel was used to

965   correct for movement during imaging with a rigid-body transformation (MultiStackReg plugin). Regions of

966   interest (ROIs) were drawn around bleached and unbleached puncta as well as region of background

967   (away from the dendritic signal). Background signal was subtracted from the puncta signal, which was

968   then normalized to the average intensity of the unbleached puncta at each timepoint (to account for the

969   low levels of acquisition bleach over time). The signal in the bleached ROIs was then normalized such

970   that the average baseline was centered on 1 and the post-bleach timepoint was 0. For each puncta the

971   estimated maximum recover was estimated with a one phase exponential fit (in GraphPad Prism 9). For

972   comparisons +/- GFP-Btbd11 analysis was performed on decoded data with just the motion-corrected

973   Psd-95-mCherry signal, so the investigator had no knowledge of the experimental condition.

974   *Analysis of puncta-to-puncta distance:*

975   Imaris 9 (Bitplane) was used to estimate the puncta-to-puncta distance shown in **Figure 1K**. The GFP

976   channel (GFP-Btbd11 knockin) with smoothing (1μm) was used to generate a surface along the dendrite

977   of the knockin cell. This surface was used as a mask for the other channel (*i.e.*, Psd-95 or Gephyrin) for

978   spot detection and analysis. The spot-detection feature was then used to detect GFP-Btbd11 and Psd-

979   95 or Gephyrin puncta. We then calculated the distance of the nearest Psd-95 or Gephyrin puncta to

980   each GFP-Btbd11 puncta (using the center of the detected spot as the center point of each punctum).

981   *Analysis of PV levels with immunofluorescence:*

982   Imaris 9 (Bitplane) was used to generate a surface around the cell body of PV-IN using PV

983   immunofluorescence signal with smoothing (2-3μm) and an estimated diameter of 5-10μm. This surface

984   was then used to calculate the average intensity of PV for each cell.

985   **Cloning and molecular biology**

986   All constructs were generated using HiFi assembly (New England Biolabs). mDlx-Azurite was generated

987   by replacing EGFP with Azurite from the pAAV-mDlx-GFP-Fishell-1 plasmid (Addgene number: 83900).

988   Generation of pORANGE Btbd11 constructs were generated using the pORANGE Cloning template

989   vector (Addgene number: 131471). The guide sequence to target the N-terminus of Btbd11 was: 5-

990   ACGGCGGCTGCAGCATGAAG-3. cDNA for mouse Btbd11 was purchased C-terminal Myc tag (Origene

991   catalog number: MR217199). Using this cDNA as template pCAG-GFP-Btbd11 was generated, removing

992   the C-terminal Myc tag (exposing the PBM of Btbd11). A linker (GGGGSGGGGTR) was added between

993   EGFP and Btbd11. The 5xANK-BTB mutant consisted of the last 512 amino acids of Btbd11 (*i.e.*, a large

994   N-terminal deletion). pCMV-Psd-95-mCherry point mutants were generated based on the mutations

995   described in (Imamura et al., 2002). pCIS-GST-Btbd11 was generated by subcloning Btbd11 into a pCIS-

996   GST expression vector. The sequence of all constructs was confirmed with DNA sequencing.

997   **Electron microscopy**

998   Cells grown in 35 mm tissue culture dishes (Falcon 3001) were briefly rinsed with 37 C PBS, then fixed

999   with 2.5 % glutaraldehyde in 100 mM phosphate buffer (Sorenson's) containing 5 mM $MgCl_2$ pH 7.4, for

000   2.5 hr. at room temperature on a slow rocker. After a 30 min buffer rinse (100 mM phosphate buffer with

001   3% sucrose and 5mM $MgCl_2$), cells were post-fixed in 1% osmium tetroxide in 100 mM phosphate buffer

002   with 5 mM $MgCl_2$ at $4^{\circ}C$ for 1 hr. in the dark. Samples were then rinsed 100 mM maleate buffer containing

003   3% sucrose pH 6.2 and en-bloc stained with 2% uranyl acetate (0.22 μm filtered) in the same buffer for

004   1 hr in the dark. Plates were dehydrated in a graded series of ethanols then infiltrated in Eponate 12

005   (Pella) overnight without catalyst. The next day cells were further embedded with fresh epon containing

006   1.5% DMP-30 (catalyst). Culture dishes were cured at $37^{\circ}C$ for three days, and further polymerized at

007   $60^{\circ}C$ overnight. Cured discs were removed from the plastic dish and 3 mm circles punched out and glued

008   to epon blanks for sectioning. 80 nm thin compression free sections were obtained with a Diatome

009   diamond knife (35 degree). Sections were picked up onto 1x2 mm formvar coated copper slot grids

010   (Polysciences), and further stained with uranyl acetate followed by lead citrate. Grids were examined on

011   a Hitachi H-7600 TEM operating at 80 Kv. Images were digitally captured with an XR-50, 5-megapixel

012   CCD camera (AMT).

013   **Generation of Btbd11 conditional KO mice**

014   *In vitro* fertilization of C57Blk/6J mice was performed by the Johns Hopkins Transgenic Core using frozen

015   sperm   obtained   from   the   European   Mutant   Mouse   Archive   (*Btbd11^tm1a(EUCOMM)Wtsi*,

016 https://www.infrafrontier.eu/). Offspring were genotyped as recommended with a common forward primer

017 (5'-3': TCCTGTCTTAATGCCCCCTG), a wildtype reverse primer (5'-3':

018 TTCTGGCGGTTCTAAATCCTG) and a mutant reverse primer (5'-3': TCGTGGTATCGTTATGCGCC).

019 Btbd11 Gene Trap mice were backcrossed with C57Blk/6J animals. To generate Btbd11 conditional

020 knockout mice, Btbd11 Gene Trap mice were crossed with constitutive FLPe-expressing animals. Correct

021 conversion was confirmed with PCR as described by the European Mutant Mouse Archive. Conditional

022 animals were bred to homozygosity. To generate IN specific knockout animals, Btbd11 conditional mice

023 (Btbd11$^{F/F}$) were crossed with vGAT^{Cre} animals (Jackson lab stock: 028862).

024 **Stereotaxic surgery**

025 *Virus injection:* pAAV-S5E2-dTom-nlsdTom virus (Addgene number: 135630) was packaged by the

026 Janelia Vector core with AAV2/9 serotype (virus titer after 1:1 dilution: 2×10^{13} GC/ml). Stereotaxic surgery

027 was conducted as previously described (Fang et al., 2021). Male and female Btbd11$^{F/F}$ or vGAT:Btbd11$^{F/F}$

028 mice aged 4-5 weeks were anesthetized with isofluorane, placed into a stereotaxic frame (Kopf) with their

029 body temperature monitored and maintained at 37°C with a closed-loop temperature control system (Kent

030 Instruments). Animals were injected subcutaneously with sterile saline (VetOne; 0.5ml) to maintain

031 hydration and buprenorphine (ZooPharm; 1 mg/kg) and lidocaine (VetOne; 2%) to provide analgesia,

032 with lidocaine injected locally under the skin over the skull. An incision was made to expose the skull with

033 a scalpel, and a craniotomy performed to expose the brain surface (see below for coordinates). Glass

034 pipettes (Drummond Science Company; Wiretrol II) were pulled (Sutter Instruments) and sharpened to a

035 30° angle (Medical Systems Corp) and used for controlled virus injection with a pneumatic injector

036 (Narishige) at a rate of 100nl/minute. After each injection the pipette was kept in place for 5 minutes

037 before being raised to the next injection depth or being removed slowly from the brain (to prevent backflow

038 of virus). To target the visual cortex the following stereotaxic coordinates and injection volumes were

039 followed, relative to bregma and pia. AP: -3.8, ML: +/-2.6, Z: -450 (200nl) and -300 (200nl). After injection

040 the skin was sutured (Ethicon) and sealed with glue (VetBond). Animals were placed in a heated cage to

041 recover with access to softened food and monitored closely. Animals were left to recover from surgery

042 (and to provide time for virus expression) for at least 12 days before being used for slice electrophysiology

043 experiments.

044 *Electrode implant:* The initial surgery was performed as described above. Male Btbd11$^{F/F}$ or

045 vGAT:Btbd11$^{F/F}$ mice aged 2-5 months were used for *in vivo* electrophysiology experiments. A craniotomy

046 was made above the V1 in the left hemisphere (AP: level with lambda, ML: 3.2) where a 50μm polyimide-

047 insulated tungsten wire was implanted at a depth of -0.45mm relative to pia. An additional craniotomy

048 was made above the cerebellum just behind lambda and just to the right of the midline for a ground

049 screw. A final craniotomy was made in the right hemisphere (AP: +1.5, ML: 0.5-0.6) for a reference

050 electrode consisting of 125μm stainless-steel coated with PTFE. Wires were connected to a mill-max

051 adaptor with metal pins and the implant secured with light-curable dental cement (3M RelyX). To enable

052 head fixation, a custom-made metal head bar was secured to the skull. Mice were left to recover for 1

053 week before habituation to handling began. After habituation to handling, mice were habituated to brief

054 periods of head fixation prior to recording sessions. Electrode placements were determined by making

055 electrolytic lesions at the conclusion of experiments which were imaged on DAPI stained brain sections

056 on a fluorescent microscope.

057 **Slice-physiology**

058 Mice were deeply anaesthetized with isoflurane. Animals irresponsive to toe pinches were decapitated,

059 and brains were rapidly extracted and sectioned using a vibratome (Leica VT-1200). The cutting ACSF

060 contained (in mM) 85 NaCl, 65 sucrose, 25 $NaHCO_3$, 10 glucose, 4 $MgCl_2$, 2.5 KCl, 1.25 NaH_2PO_4, 0.5

061 $CaCl_2$ (pH 7.35, ~308mOsm). 300 μm horizontal slices containing the prelimbic cortex were collected

062 and recovered for 10min in cutting ACSF at 32°C, after which slices were transferred to ACSF solution

063 containing (in mM) 130 NaCl, 24 $NaHCO_3$, 10 glucose, 3.5 KCl, 2.5 $CaCl_2$, 1.5 $MgSO_4$, 1.25 NaH_2PO_4 (pH

064 7.35, ~303mOsm). Slices were left to recover for 1h at room temperature before recordings. All ACSF

065 solutions were saturated with 95% O2 and 5% CO2. For recording, a single slice was transferred to a

066 heated chamber (34-35°C) and perfused with ACSF using a peristaltic pump (WPI). tdTomato-expressing

067 cells in the visual cortex were identified on an upright microscope equipped for differential interference

068 contrast (DIC) microscopy (Olympus BX51WI) and LED fluorescence (X-Cite, 120 LED). Whole-cell

069 patch-clamp recordings were made using a MultiClamp 700B amplifier (1kHz low-pass Bessel filter and

070 10kHz digitization) with pClamp 10.3 software (Molecular Devices). Voltage-clamp recordings were made

071 using borosilicate glass pipets (King Precision Glass Inc., KG-33 ID1.00 OD 1.50) with resistance 2.0-

072 3.0MΩ, filled with internal solution containing (in mM): 117 Cs-methanesulphonate, 20 HEPES, 5 QX-

073 314, 5 TEA-Cl, 4 ATP-Mg, 2.8 NaCl, 1 Na_2-phosphocreatine, 0.4 EGTA, 0.4 GTP-Na (pH

074 7.30, ~290 mOsm). Access resistance was continually monitored throughout recording; cells in which

075 access resistance rose above 20MΩ were excluded from analysis. Membrane potentials were not

076 corrected for junction potentials.

077 Recordings were conducted in the presence of the GABA receptor antagonist SR-95531 (5 μM) to isolate

078 glutamatergic currents. Electrical stimuli were delivered using a bipolar stimulating electrode (FHC,

079 MX21AES) placed lateral to the recorded cell. Analysis was performed offline using Clampfit (v 10.6) and

080 MiniAnalysis (v 6.0.7, Synaptosoft).

081 **Ca^{2+} imaging and analysis**

082 Mouse Btbd11$^{F/F}$ hippocampal cultures transduced with AAV-GFP or AAV-GFP-Cre and AAV-jRGECO1a

083 were transferred to ACSF (recipe as above) and allowed to equilibrate for 10-15 mins before being

084 imaged in a temperature and humidity-controlled chamber. Images (512x512 pixels) were acquired with

085 a 10x objective at 4Hz for 60s from multiple regions of interest for each coverslip. In FIJI, each timeseries

086 was projected to a single plane (maximum intensity projection) to aid identifying the soma of neurons. A

087 square/rectangle was drawn at the cell body of neurons and assigned as ROIs. ROIs were then opened

088 on the original timeseries which was median filtered (0.5 pixels). The mean signal intensity was extracted

089 for each neuron in the field of view. Data were then processed with custom written Python scripts using

090 Jupyter notebooks to: 1) convert the signal to represent dF/F assigning F_0 as the 10th percentile of the

091 signal, 2) calculate the average dF/F of all neurons in each imaging region to capture the synchronous

092 activity, 3) convert the data to a z-score, 4) subtract the minimum value from each timepoint to center the

093 baseline around 0, and 5) use find_peaks and peak_prominences (from scipy library) with parameters

094 [height threshold = 2, distance threshold = 8, prominence threshold = 1] to automatically identify

095 spontaneous activity in the cultures.

096 **In vivo recordings**

097 Following habituation to handling and head fixation, mice (5 control and 6 knockout) were head restrained

098 and presented with a monitor positioned at 45° with respect to their right eye. As a visual stimulation,

099 mice were presented with a black screen or a gray screen for 90s. Recordings were made with a 32-

100 channel RHD2132 head stage (Intan Technologies, CA, US) via a custom-built adaptor and an Open

101 Ephys acquisition board via an SPI-cable (Intan Technologies). Data were amplified and digitized by the

102 RHD2132 headstage, sampled at 30kHz, and digitally bandpass filtered between 0.1–300 Hz before

103 further processing in Matlab (Mathworks) and custom written scripts in Jupyter notebooks. Data were

104 down sampled to 1kHz and power analyzed with *compute_spectrum* and *specgram* from the Neurodsp

105 and matplotlib libraries, respectively. The mean and peak 55Hz-65Hz power was calculated with

106 presentation of the black or gray screen and converted to a gray/black screen ratio.

107 **Behavioral testing**

108 Animals were housed in a holding room on a reverse light cycle. Testing was conducted during the dark

109 phase after animals were habituated to handling. Mice were aged between 5 – 6 months at the time of

110 testing. For locomotor activity and spontaneous alternation, we tested 13 control (9 female and 4 male)

111 and 10 knockout (6 female and 4 male) animals. For the MK-801 challenge we used 9 control (5 female

112 4 male) and 7 knockout (3 female and 4 male) mice.

113 *Locomotor activity:* Locomotor activity was assessed by placing animals in an open field arena (40x40cm)

114 in the dark and measuring the number of infrared beam breaks during a 90-minute session (San Diego

115 Instruments Inc.). Data were binned into 5-minute periods for analysis.

116 *Y-maze spontaneous alternation:* Spatial short-term memory was assessed in the Y-maze spontaneous

117 alternation task. Mice were placed at the end of one arm of a Y- maze consisting of three 38cm long arms

41

118　(San Diego Instruments Inc) and allowed to freely explore the maze for 5 minutes. Animal location was

119　automatically recorded and tracked using Anymaze Tracking Software (Stoelting). The percent of

120　spontaneous alternation was calculated using the equation: % alternation = (total alternations/(total arm

121　entries -2))×100.

122　*Locomotor activity with MK-801 challenge:* Activity was assessed as above, except the area was

123　illuminated animals received an intraperitoneal injection of saline or MK-801 maleate (0.2mg/kg; Tocris).

124　A within-subject design was followed, and the test was repeated 2-days later with drug assignment

125　reversed. The order of saline vs. MK-801 was counterbalanced for genotype.

126　**Statistical analysis**

127　GraphPad Prism 9 was used for all statistical analyses. Figures were plotted in Prism 9 or using Python

128　and Jupyter Notebooks. Images were processed in FIJI (Schindelin et al., 2012) and often presented as

129　maximum intensity projections. Images were frequently median filtered to reduce noise. Any adjustment

130　of brightness and contrast was performed uniformly across the image. Figures were assembled in Adobe

131　Illustrator. Details of all statistical tests can be found in **Table S2**. To reduce the chance of bias, FRAP

132　and mEPSC analyses were performed on decoded files and behavioral experiments were conducted by

133　an investigator that was unaware of the genotype of the animals being tested. Data were assumed to

134　follow the normal distribution, but no formal tests of normality were conducted.

135